Elucidating The Smoking Cessation Process Among Socioeconomically Disadvantaged Smokers With Serious Mental Illness by Hammett, Patrick
  
Elucidating The Smoking Cessation Process Among Socioeconomically Disadvantaged 
Smokers With Serious Mental Illness 
 
 
A DISSERTATION  
SUBMITTED TO THE FACULTY OF 
UNIVERSITY OF MINNESOTA 
BY 
 
 
 
 
 
Patrick John Hammett 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
Harry A. Lando, PhD, Advisor 
 
March 2018 
 
 
  
 
 
 
 
 
 
© Copyright by Patrick John Hammett  
2018 
	 i 
Acknowledgements 
I would like to express my sincere gratitude to Drs. Harry Lando and Steven Fu for their 
guidance and mentorship over the past four years. Harry has been invaluable in helping 
me navigate the hurdles of the PhD program, and his expertise in the field of tobacco 
research has greatly elevated the quality of every project I have collaborated with him on. 
Steve has been an amazingly knowledgeable resource, a constant source of motivation, 
and has helped me develop and hone a clear career path. I would also like to thank the 
rest of my dissertation committee Drs. Darin Erickson, Brent Taylor, and Rachel Widome 
for their guidance and feedback on this dissertation. Rachel has been a great mentor and I 
can only hope some of her teaching abilities rubbed off on me during my stint as her 
teaching assistant.  
 
 
 
 
 
 
 
 
	 ii 
Dedication 
This dissertation is dedicated to my family, friends, and canine companions who have 
supported me through the years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 iii 
Abstract 
Introduction 
The decline in smoking prevalence has been paralleled by widening mental health and 
socioeconomic disparities in smoking rates.1 To identify points of intervention, this 
dissertation presents three studies that elucidate the smoking cessation process among 
socioeconomically disadvantaged smokers with serious mental illness (SMI).  
Methods 
The following studies are secondary data analyses of the OPTIN study. ICD-9 codes 
categorized participants into SMI (n=1044) and non-SMI (n=1277) groups. The first 
study utilized mediation analysis to examine whether physician cessation treatment 
advice and physician bias mediate the association between SMI and treatment utilization. 
The second study utilized logistic regression to examine the intervention effect among 
smokers with and without SMI, and whether it was more effective for smokers with SMI. 
Using multinomial and linear regressions, the third study examined how smoking 
abstinence affects binge drinking and mental health among smokers with and without 
SMI.  
Results 
In the first study, smokers with SMI utilized treatments at higher rates than those without 
SMI. This effect was mediated by physician treatment advice (Proportion 
Mediated=11.7%), but not bias. In the second study, the intervention increased treatment 
utilization in the SMI (51.6% vs 38.1%) and the non-SMI group (38.6% vs 25.8%). The 
	 iv 
intervention increased abstinence in the non-SMI group (18.1% vs 12.8%) and the SMI 
group (14.7% vs 10.8%). There were no significant interactions. In the third study, 
smokers who quit had lower odds of binge drinking for more than 3 days per month in 
the SMI (OR = 0.26) and the non-SMI group (OR = 0.42). Smokers who quit had lower 
depression scores in the SMI (2.37 vs 2.71) and the non-SMI group (1.59 vs 1.75). In the 
SMI group, smokers who quit reported lower anxiety scores (55.61 vs. 59.03). 
Discussion 
These studies highlight the importance of healthcare providers in the cessation process, 
demonstrate that proactive outreach is effective for treatment utilization and abstinence, 
and provide evidence for beneficial effects of smoking abstinence in the domains of 
mental health and alcohol use. These findings underscore the need to facilitate access and 
utilization of cessation treatments among smokers with mental illness.   
 
 
 
 
 
 
 
 
	 v 
Table of Contents 
List of Tables   Page vi 
List of Figures   Page viii 
List of Appendices   Page ix 
Background   Page 1 
Source of Data  Page 9 
Research Study 1  Page 14 
Research Study 2  Page 40 
Research Study 3  Page 71 
Conclusion    Page 102 
Bibliography    Page 110 
Appendix   Page 127 
 
 
 
 
 
 
 
 
 
 
 
	 vi 
List of Tables 
Table 1. Baseline Characteristics of the OPTIN Sample 
 Page 11 
 
Table 2. Measures and Data Collection Schedule 
 Page 13 
 
Table 3. Baseline Demographic, Smoking History, Social Environment, Healthcare 
Provider, and Cessation Belief Characteristics of SMI vs Non-SMI Smokers 
 Page 27 
 
Table 4. Cessation Treatment Utilization of SMI vs Non-SMI Smokers at 12-Month 
Follow-Up 
 Page 29 
 
Table 5. Correlation Across Mediators 
 Page 29 
 
Table 6. Mediation Effects for Physician Advice and Physician Bias Mediators and 
Treatment Utilization Outcomes 
 Page 34 
 
Table 7. Cessation Treatment Utilization of SMI vs Non-SMI Smokers at 12-Month 
Follow-up Adjusting for Clinical Encounters 
 Page 35 
 
Table 8. Characteristics of Follow-Up Survey Responders Vs. Non-Responders 
 Page 57 
 
Table 9. Baseline Demographic, Smoking History, Social Environment, Healthcare 
Provider, and Cessation Belief Characteristics of SMI vs Non-SMI Smokers 
 Page 60 
 
Table 10. Effect of Proactive Outreach on Cessation Treatment Utilization and Prolonged 
Abstinence 
 Page 62 
 
Table 11. Cessation Treatment Utilization and Prolonged Abstinence in SMI Group 
 Page 63 
 
Table 12. Cessation Treatment Utilization and Prolonged Abstinence in Non-SMI Group 
 Page 65 
 
 
	 vii 
Table 13. Intervention, Demographic, Social Environment, and Smoking 
History/Cessation Beliefs Characteristics of Smoking Quitters Vs. Non-Quitters 
 Page 82 
 
Table 14. Baseline Demographic, Mental Health/Alcohol, Smoking History, Social 
Environment, Healthcare Provider, and Cessation Belief Characteristics of SMI vs. Non-
SMI Smokers 
 Page 85 
 
Table 15. Binge Drinking at Follow-Up in Smoking Quitters vs Non-Quitters by SMI 
Group 
Page 88 
 
Table 16. Binge Drinking at Follow-Up in Smoking Quitters vs Non-Quitters in 
Combined Sample 
 Page 91 
 
Table 17. PHQ-2 Depression Scores at Follow-Up in Smoking Quitters vs Non-Quitters 
by SMI Group 
Page 93 
 
Table 18. PROMIS Anxiety Scores at Follow-Up in Smoking Quitters vs Non- Quitters 
by SMI Group 
Page 95 
 
 
 
 
 
 
 
 
 
 
 
 
	 viii 
List of Figures 
Figure 1. Mediation Models and Timeline of Measures. 
 Page 24 
 
Figure 2. Summary of Effects for Physician Advice to Use Medication Mediator and 
Medication Use Outcome 
 Page 30 
 
Figure 3. Summary of Effects for Physician Advice to Use Medication Mediator and 
Any Treatment Use Outcome 
 Page 30 
 
Figure 4. Summary of Effects for Physician Advice to Use Other Treatments Mediator 
and Counseling Use Outcome 
 Page 31 
 
Figure 5. Summary of Effects for Physician Advice to Use Other Treatments Mediator 
and Any Treatment Use Outcome 
 Page 31 
 
Figure 6. Summary of Effects for Perception of Physician Bias Advice Mediator and 
Any Treatment Use Outcome 
 Page 31 
 
Figure 7. Conceptual Framework Describing a Proactive Outreach Intervention for 
Smoking Cessation. 
Page 52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 ix 
List of Appendices 
Scale 1. Perceptions of Healthcare Provider Bias 
 Page 123 
 
Scale 2. Binge Drinking Behavior 
 Page 124 
 
Scale 3. Patient Health Questionnaire (PHQ-2) 
 Page 125 
 
Scale 4. Patient Reported Outcomes Measurement Information System (PROMIS) 
anxiety 7a 
 Page 126 
 
 
 
 
 
 
 
 
 
 
	 1 
Background 
A Health Disparity Priority 
The Health and Economic Burdens of Smoking 
There has been a gradual decline in the prevalence of cigarette smoking in the US over 
the past several decades, with a current estimated prevalence of 17%.1 Despite this 
decline, smoking still accounts for approximately 480,000 premature deaths and 300 
billion dollars in healthcare costs and lost productivity each year in the US.2 These 
figures are made more troubling due to the fact that tobacco-related burdens are borne 
disproportionately by those of lower socio-economic status (SES), certain racial and 
ethnic minorities, those who identify as gay, bisexual, or transgender, and those with 
mental illness.1  
Smoking, SES, and Mental Illness 
The overall decline in smoking prevalence has been paralleled by a widening 
socioeconomic disparity in smoking rates. Among US adults under the age of 65, 30% of 
the medically uninsured and Medicaid enrollees are current cigarette smokers, compared 
to 15% of adults with private health insurance.3 Socioeconomic disadvantage is also 
associated with increased rates of mental illness, as the prevalence of many mental health 
(MH) disorders are far higher among low-income populations,4,5  those who did not 
complete high school,6 and the unemployed.7  
The co-occurrence of socioeconomic disadvantage and mental illness is especially 
troubling given evidence suggesting that mental illness is a strong risk factor for smoking 
	 2 
in its own right. Indeed, rates of smoking among those with a MH disorder are two to 
three times higher than that of the general US population depending on clinical 
diagnosis.8 In addition, those with MH disorders smoke with greater frequency, intensity, 
and are more nicotine-dependent than smokers without MH disorders.9 The highest rates 
of smoking are found among those with diagnoses of schizophrenic disorders, major 
depressive disorders, and bipolar depression, suggesting that diagnoses consistent with 
serious mental illness (SMI) confer the greatest smoking risk.10–12 As a result, cigarette 
smoking is the primary cause of excess mortality in this population.13,14 As low SES and 
mental illness contribute independently to smoking risk,15 socioeconomically 
disadvantaged smokers with MH disorders are an exceptionally vulnerable population 
with respect to smoking-related morbidity and mortality. 
Cessation Treatment for Smokers with SMI 
Historically, there have been a dearth of studies devoted to evaluating the effectiveness of 
cessation treatments for smokers with SMI as these smokers are often excluded from 
participating in cessation trials, particularly those involving novel or high-risk 
treatments.16 However, increased attention to this disparity in recent years has helped to 
demonstrate the effectiveness of multiple cessation treatment modalities for this 
population.17  
Effectiveness of Cessation Treatment. 
Several studies have demonstrated the effectiveness of nicotine replacement therapy 
(NRT) among mixed-MH disordered samples,18–20 and have even demonstrated that the 
abstinence rates achieved by smokers with MH disorders can be similar to those 
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experienced by smokers without MH disorders.20 Varenicline has also been shown to be 
an effective treatment when used in conjunction with NRT in a mixed-MH disorder 
sample,18,20 and Bupropion has been shown to be effective when used in conjunction with 
NRT and group therapy among smokers with schizophrenia.21 With respect to non-
pharmacological cessation treatments, cognitive behavioral therapy and contingency 
management techniques have demonstrated effectiveness among mixed-MH disorder 
samples,18 as well as among smokers with depression22,23 and schizophrenia.24,25 In 
addition, contingency management techniques are effective for boosting abstinence rates 
among mixed-MH disorder samples.19 
Studies further suggest that smokers with SMI are receptive to cessation treatments and 
take these treatments up at high rates when they are offered.26–28 Particularly high rates of 
treatment up-take can be achieved when offered in a proactive and universal manner.27 In 
summary, considerable evidence suggests that both pharmacological and counseling-
based treatments are effective and well-tolerated among smokers with SMI.  
Healthcare Provider Factors and Cessation Treatment Utilization 
One potentially important barrier to treatment utilization among smokers with SMI is 
their interactions with healthcare providers.  
SMI and Healthcare Provider Interactions 
Individuals with SMI often do not receive the care they need, a problem that is partially 
attributable to the inherent complexities of the healthcare and insurance systems in the 
US, factors which make it more difficult for them to initiate and maintain care.29 Those 
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with SMI tend to receive lower rates of care from healthcare providers, particularly with 
respect to care for co-morbid health conditions. Indeed, SMI is associated with a lower 
probability of being referred for mammography, inpatient services following a diabetic 
crisis, and cardiac catheterization.30,31  
Healthcare Provider Barriers: Advice. 
Evidence suggests that the issue of differential care extends to treatment for smoking 
cessation. Although the 2008 United States Department of Health and Human Services 
(USDHHS) clinical practice guideline states that smokers with MH disorders should be 
offered the same cessation treatment options as smokers without these disorders,32 in 
practice this is rarely the case. Smokers with SMI receive low rates of cessation 
counseling,33 and smokers with less severe diagnoses like anxiety disorders are more 
likely to receive cessation care than those with more severe diagnoses like 
schizophrenia.34 Several factors may account for this disparity in care. Historically, 
smoking has been perceived as a normative behavior for smokers with SMI, particularly 
among staff working in in-patient psychiatric units.35,36 Furthermore, healthcare 
professionals may discourage quitting due to a belief that this may exacerbate these 
patients’ depressive symptoms.37,38 In addition, physicians face competing treatment 
concerns for these patients, lending to the perception that smoking cessation is not a 
priority for these individuals.38,39 This “treatment overshadowing”, in which a physician 
prioritizes treatment of MH symptoms over other health concerns,40 may contribute to 
lower rates of cessation-related care for this group.  
Healthcare Provider Barriers: Bias.  
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The internalization of mental health stigma and bias on the part of the healthcare provider 
may also play a role in engendering differential care for those with SMI.41 Studies have 
indicated that physicians are less comfortable interacting with patients with MH 
disorders,31,42 and that some hold discriminatory beliefs toward these patients.31 Other 
research has shown that physicians who have a patient with a history of a MH disorder 
are less likely to take their medical problems seriously,43 and that physician endorsement 
of MH stigma is associated with a lower likelihood of specialist referral and a reduced 
willingness to refill prescriptions.44,45 The problem of being unable to obtain prescriptions 
may be exacerbated for smokers enrolled in publicly-subsidized healthcare programs, as a 
prescription from a healthcare provider is required in order to receive free or reduced cost 
cessation treatment. Indeed, Medicaid enrollees are much less likely to utilize 
pharmacotherapy than the general population.46 
Barriers to Cessation  
Proactive outreach strategies may be useful in helping to address the unique individual, 
social environment, and healthcare provider barriers to cessation faced by smokers with 
SMI. 
Individual Level Barriers 
At the individual level, the “self-medication” hypothesis posits that individuals with 
mental illness smoke in an attempt to reduce the experience of negative affect and anxiety 
associated with their condition,47,48 factors which could reduce the likelihood of engaging 
in a quit attempt. Smokers with SMI also experience heightened nicotine withdrawal 
symptoms when trying to quit including depressed mood, anxiety, and generalized 
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discomfort.49,50 With respect to psychosocial profile, evidence suggests that smokers with 
mental illness have lower self-efficacy for quitting35,51,52 which contributes to a perceived 
inability to initiate and maintain abstinence.  
Social Environment Barriers 
With respect to social environment, smoking is often seen as a normative and socially-
acceptable behavior for those with SMI and has even been encouraged among those 
living in in-patient psychiatric units.35,36 Indeed, cigarettes have been used as a reward to 
reinforce acceptable behavior among patients in treatment settings.53 Individuals with 
certain MH disorders may also be more susceptible to peer influence regarding smoking. 
In a study of adolescents, more severe symptoms of depression were associated with 
greater peer acceptability of smoking.36  
Healthcare Provider Barriers 
Evidence suggests that smokers with SMI receive differential care from their healthcare 
providers. Physicians face competing treatment demands for these patients, lending to the 
perception that smoking cessation is not a priority for these individuals.38,39 The 
internalization of mental health stigma by physicians may also lead to a different standard 
of care for smokers with SMI.41 Several studies have indicated that physicians are less 
comfortable interacting with patients with MH diagnoses31,42 and that some hold 
discriminatory beliefs toward these patients.31 Finally, research has shown that some 
physicians expect that the mental health of their patients will deteriorate if they attempt 
cessation,37,38 leading to a reluctance to provide cessation advice.  
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Proactive Outreach: Overcoming Cessation Barriers 
Proactive outreach cessation strategies, which promote heightened contact with smokers, 
facilitate access to free pharmacological cessation treatment, and provide motivational 
quitting advice as well as promote self-efficacy, may be an effective approach for 
minimizing psychosocial and healthcare provider barriers to treatment among smokers 
with SMI. With respect to psychosocial barriers, the motivational interviewing 
components of the intervention are designed to improve smokers’ self-efficacy for 
quitting as well as address social environmental barriers like permissive social network 
norms and low social support for quitting. In terms of healthcare provider barriers, 
proactive outreach may help overcome the issues of competing treatment demands, the 
perception that smokers with SMI aren’t motivated to quit, and the low rates of specialist 
referral experienced by smokers with SMI by facilitating easy access to evidence-based 
cessation resources.  
Evaluating the Effects of Smoking Cessation 
To address the perception that smoking cessation is not a treatment priority, we must 
critically examining some of the enduring beliefs regarding smoking cessation among 
those with SMI. Specifically, it is important to evaluate how the smoking cessation 
process influences the MH of those with SMI and whether it contributes to an increase in 
other problematic health behaviors. 
Mental Health 
A key barrier to smoking cessation among those with SMI is the perception that quitting 
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will exacerbate the MH symptoms associated with their condition. This perception exists 
at the individual level and at the level of the healthcare provider. Smokers with SMI often 
use nicotine as a form of self-medication to help reduce the experience of negative affect 
and anxiety associated with their condition(s),47,48 while other research suggests that these 
smokers believe that their MH will deteriorate following a quit attempt.35 Healthcare 
providers similarly endorse the belief that quitting may heighten the depressive 
symptoms of their patients,37,38 contributing to the belief that smoking cessation is not a 
treatment priority for these patients.  
Binge Drinking 
At the individual level, many of those with alcohol use disorder report using tobacco as a 
way of coping with the urge to drink,54 making the prospect of quitting smoking seem 
overwhelming and unattainable. At the level of the healthcare provider, the strong 
withdrawal symptoms associated with abstinence from both tobacco and alcohol have 
contributed to a reluctance to treat these conditions simultaneously,55,56 largely due to the 
belief that achieving abstinence in one of these behaviors will lead to exacerbation of the 
other.57 By exploring how smoking cessation affects the highly co-morbid issue of binge 
drinking, we can evaluate what impact smoking cessation has on other problematic health 
behaviors and how physicians should address these issues during the cessation process.  
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Source of Data 
Data for the following studies are taken from the “Improved Effectiveness of Smoking 
Cessation Programs for Minnesota Priority Populations” (OPTIN) trial.  
Study Design 
OPTIN is a randomized controlled trial that demonstrated the effectiveness of a proactive 
outreach intervention for boosting rates of cessation treatment utilization and prolonged 
abstinence among a sample of socioeconomically disadvantaged smokers enrolled in 
Minnesota Health Care Programs (MHCP). MHCP is a health insurance program for low-
income persons and families that is comprised of two major publicly-subsidized health 
care assistance programs: Medicaid and MinnesotaCare. The study population sample 
was stratified by age group (18–24, 25–34, and 35–64), gender, and healthcare program 
(Medicaid and MinnesotaCare). Institutional Review Board (IRB) approval for the study 
was obtained from the University of Minnesota and the Minnesota Department of Human 
Services (DHS). 
Sampling Procedure  
Prospective participants aged 18 and older were identified using MHCP administrative 
data from the Minnesota DHS. A random sampling procedure identified 21,181 potential 
participants out of a total of 630,000 MHCP enrollees. These individuals were mailed a 
tobacco use survey that served as both an eligibility screen and baseline survey.  
Sample 
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Eligibility criteria included 1) a valid home address, 2) proficiency in English, and 3) 
current cigarette smoking (having smoked a cigarette in the past 30 days, even a puff). 
Baseline surveys were mailed to 21,181 prospective participants aged 18 to 64 who were 
MHCP enrollees. 9,362 baseline surveys were returned. Of these, 6,826 did not meet 
study inclusion criteria and 130 declined to participate. The remaining smokers 
(N=2,406) were enrolled in the study and randomized to proactive outreach (n=1200) or 
usual care (UC) (n=1206). 
Participant Characteristics 
The majority of the sample was enrolled in Medicaid (73%) at the time of the baseline 
survey Most of the sample was female (70%), and the racial composition was majority 
White (78%) with large groups of African American (11%) and American Indian (7%) 
participants. A significant proportion of participants had completed at least some college 
(42%), and most of the sample (69%) earned less than $20,000 annually. Slightly less 
than half of the sample (43.4%) had at least one SMI diagnosis, defined as: Schizophrenia 
spectrum disorder, psychotic disorder, major depressive disorder, and/or bipolar I or II 
disorder (see Table 1). 
With respect to smoking characteristics, the majority of participants (70%) smoked a 
cigarette within 30 minutes of waking. Most participants (54%) reported having made a 
quit attempt within the past year at baseline. Only 31% of participants reported having 
used any form of cessation treatment within the past year, with the vast majority 
reporting that they had used some form of pharmacotherapy (NRT, prescription 
medication). 
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Table 1. Baseline Characteristics of the OPTIN Sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristic 
N=2406 
No. (%) or Mean 
Demographics  
Insurance type  
Medicaid 1,749 (72.7) 
MnCare 657 (27.3) 
Male 707 (29.4) 
Race/Ethnicity  
White 1,885 (78.4) 
Black or African American 256 (10.6) 
Amer Indian or Alaskan Native 167 (6.9) 
Hispanic or Latino 42 (1.8) 
Asian or Pacific Islander 56 (2.3) 
SMI Diagnosis  
Major depression 835 (34.7) 
Bipolar 440 (18.3)                            
Schizophrenia 146 (6.1) 
Psychotic 164 (6.8) 
Any 1044 (43.4) 
Education  
Grade 11/lower                                                                                                                                                                                                                                                                        322 (13.7) 
HS grad/GED 781 (33.2) 
Some college 977 (41.5) 
College grad/higher 274 (11.6) 
Employment   
Employed/self-employed 1,206 (51.1) 
Student 162 (6.9) 
Out of work 307 (13.0) 
Unable to work/disabled 553 (23.4) 
Homemaker 133 (5.6) 
Yearly income  
Less than $10k 857 (37.3) 
$10,001-$20k 720 (31.4) 
$20,001-$40k 492 (21.4) 
More than $40k 228 (9.9) 
Smoking History  
Cigs/day 13.6  
Time until 1st cig (mins)  
≤ 5 617 (26.0) 
6 – 30 1045 (44.0) 
> 30  715 (30.0) 
Past year quit attempt 1287 (54.3) 
Any treatment used 752 (31.3) 
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Data Collection Procedures 
Data were collected from MHCP administrative and claims data obtained from the 
Minnesota DHS for a 2-year period prior to study initiation, and using mailed surveys at 
baseline (i.e. at time of randomization) and at 12 months post-randomization. A modified 
Dillman sequential mixed mode protocol (mailed questionnaire plus telephone follow-up) 
was used, including a $10.00 incentive that was included with the first mailing of the 
follow-up survey. 944 participants (78%) in UC and 826 participants (69%) in proactive 
outreach returned their 12-month follow-up survey (see Table 2). 
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Table 2. Measures and Data Collection Schedule 
MEASURES Pre Baseline 12-M Source 
Demographics     
Insurance 
x x  DHS 
Admin 
Sex  x x 
Survey 
Age  x x 
Race/ethnicity  x x 
Employment status  x x 
Educational level  x x 
Household income  x x 
Smoking history    
Survey 
 
Age began to smoke regularly  x  
Quit attempt in past 12 months  x x 
Number of days smoked in past 30 (Youth Tobacco 
Survey-CDC) 
 x x 
Smoking outcomes     
6 month prolonged abs   x Survey 
Nicotine dependence     
CPD (cigarettes per day) (Partial Cigarette Dependence 
Scale) 
 x x 
Survey Time of first cigarette in the morning (Partial Cigarette 
Dependence Scale) 
 x x 
Treatment utilization      
Use of smoking cessation services in past 12 months  x x 
Survey Use of meds/NRT past 12 months  x x 
Use a tele stop smoking program in past 12 months  x x 
Healthcare provider     
Have a regular healthcare provider  x x 
Survey 
Saw a healthcare provider in the past 12 months  x x 
Doctor advise to quit  x x 
Doctor discuss ways to quit (other than meds)  x x 
Doctor discuss medications  x x 
Satisfaction with help received about quitting smoking  x x 
Provider bias and cultural competence  x x 
Cessation beliefs     
Readiness to quit ladder (RQL) (contemplation ladder)  x x Survey Global self-efficacy (SEG)  x x 
Social environment      
Other people in household  x  
Survey 
Other household smoker  x x 
Smoking rules in home  x x 
Friends that smoke  x  
Important peoples’ attitudes toward your smoking  x  
Social undermining/social support  x  
Mental health     
Alcohol use (BRFSS and DoD)   x x 
Survey Depression symptoms PROMIS Anxiety Scale)  x x 
Anxiety symptoms    
Mental health disorder  
x   DHS 
Admin 
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Research Study 1 
Title: Serious mental illness and cessation treatment utilization: 
The mediating role of healthcare provider interactions 
Specific Aims 
Aim 1: To explore the effect of SMI on cessation treatment utilization. 
Hypothesis 1: SMI will be negatively associated with cessation treatment 
utilization. 
Aim 2: To explore the roles of 1) physician-delivered cessation advice, and 2) 
perceptions of physician bias as potential mediators of the effect of SMI on cessation 
treatment utilization. 
Hypothesis 2(i): A significant amount of the total effect of SMI on change in 
cessation treatment utilization rates will be mediated by its indirect effect on 
physician-delivered cessation advice. 
Hypothesis 2(ii): A significant amount of the total effect of SMI on change in 
cessation treatment utilization rates will be mediated by its indirect effect on 
perceptions of physician bias. 
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Abstract 
Introduction 
Evidence suggests that patients with SMI receive differential care from their healthcare 
providers for co-morbid health conditions, and that physicians may be reluctant to treat 
smoking cessation as a healthcare priority for those with SMI. The purpose of the present 
study is to elucidate the role that healthcare provider interactions play in the cessation 
process for smokers with SMI, in an effort to identify points of intervention that may be 
effective for this population. 
Methods 
Data for this secondary data analysis were taken from the OPTIN study. ICD-9 codes 
consistent with diagnoses of schizophrenic disorders, psychotic disorder, bipolar 
disorders, and/or major depressive disorder were used to categorize participants in SMI 
(n=1044) or non-SMI (n=1277) groups. Mediation analyses assessed whether the effect 
of SMI on cessation treatment utilization at 12-month follow-up was mediated by 
baseline measures of physician-delivered cessation advice and perceptions of physician 
bias, respectively. 
Results 
Contrary to expectation, smokers with SMI utilized cessation treatments at higher rates 
than those without SMI. Smokers with SMI reported higher rates of physician-delivered 
advice to use cessation treatments, effects that were associated with higher rates of 
cessation treatment utilization. In minimally adjusted models, the effect of SMI on any 
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form of cessation treatment utilization was partially mediated by advice to use 
medications (Proportion Mediated=11.7%) and by advice to use other forms of treatment 
(Proportion Mediated=6.0%). Mediation by physician bias was not present.  
Discussion 
The association between physician advice to use cessation treatment and cessation 
treatment utilization highlights the important role that healthcare providers play in the 
cessation process. These results suggest that the patient/physician relationship is an 
important point of intervention for low-income smokers, and that continued effort is 
needed to minimize barriers to cessation-related care. This is particularly important for 
smokers with SMI, who tend to be interested in quitting but may need more help from 
healthcare professionals in order to achieve prolonged smoking abstinence.  
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Introduction 
The overall decline in smoking prevalence has been paralleled by widening 
socioeconomic and mental health disparities in smoking rates. Among adults under the 
age of 65, 30% of the medically uninsured and Medicaid enrollees are current cigarette 
smokers, compared to 15% of those with private health insurance.3 Socioeconomic 
disadvantage is also associated with heightened rates of mental illness, as the prevalence 
of MH disorders are higher among low income populations,4,5 those who did not 
complete high school,6 and the unemployed.7 As low socioeconomic standing and mental 
illness are independently associated with smoking,15 socioeconomically disadvantaged 
smokers with SMI are an exceptionally vulnerable population with respect to smoking-
related morbidity and mortality. 
Increased attention to these disparities has helped to demonstrate the effectiveness of 
multiple forms of treatment for this population. NRT has been shown to be effective in 
mixed-MH disordered samples,18–20 leading to abstinence rates similar to those 
experienced by non-MH smokers.20 Studies have also shown that Varenicline and 
Bupropion, used in conjunction with NRT, are effective for smokers with MH 
disorders.18,20,21 Cognitive behavioral therapy has been shown to be effective in mixed-
MH disorder samples,18 as well as among smokers with depression22,23 and 
schizophrenia.24,25 In addition, research has demonstrated that motivational interviewing 
is an effective cessation treatment for smokers with major depression.58   
Considerable evidence suggests that pharmacological and counseling-based treatments 
are effective and well-tolerated by smokers with SMI, but reducing smoking disparities 
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requires a thorough examination of the barriers and facilitators to their use. One 
important factor is these smokers’ interactions with their healthcare providers. Although 
the 2008 USDHHS clinical practice guideline states that smokers with MH disorders 
should be offered the same cessation treatment options as smokers without these 
disorders,32 evidence suggests that they do not receive that same level of cessation-related 
treatment and advice from their healthcare providers.33,34,59  
Several factors may account for this potential disparity in care. Physicians face 
competing treatment demands for these patients, lending to the perception that smoking 
cessation is not a priority for these individuals38,39 and potentially contributing to lower 
rates of cessation-related care for this group. The internalization of mental health stigma 
on the part of physicians can also play a role in engendering differential care for those 
with SMI.41 Several studies have indicated that physicians are less comfortable 
interacting with patients with MH diagnoses31,42 and that some hold discriminatory 
beliefs toward these patients.31 Physician endorsement of MH stigma is associated with a 
lower likelihood of specialist referral and a reduced willingness to refill prescriptions.44,45 
The problem of being unable to obtain prescriptions may be exacerbated for smokers 
with SMI who are enrolled in Minnesota Health Care Programs (MHCP), as a 
prescription from a healthcare provider is required in order to receive free or reduced cost 
cessation treatment. 
Despite evidence suggesting that both pharmacological and counseling cessation 
treatments are effective for smokers with SMI, little is known about their rates of 
cessation treatment utilization. As such, an initial aim of this study is the explore rates of 
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cessation treatment utilization among smokers with and without SMI.  
Furthermore, while smokers with SMI who are enrolled in MHCP have access to free and 
reduced cost cessation treatments, a lack of adequate cessation-related care from 
healthcare providers may act as a barrier to cessation treatment utilization. Given the 
heightened rates of smoking-related morbidity and mortality among smokers with SMI, it 
is critically important that we better understand the effect that these interactions have on 
the cessation process. As such, our primary aim is to elucidate the mechanisms that 
contribute to cessation treatment utilization among smokers with SMI relative to those 
without SMI, with a focus on healthcare provider interactions. Specifically, we will 
explore the roles of physician advice to use medications and advice to use other cessation 
treatment options, as well as perceptions of physician bias, as potential mediators of the 
effect of SMI on cessation treatment utilization. As eliminating smoking would prevent a 
large amount of the excess morbidity and mortality experienced by this population,60,61 it 
is imperative that we continue to identify points of intervention that can be used to help 
eliminate this health disparity. 
Methods 
Study Design 
Data were obtained from the OPTIN study. The study population sample was stratified by 
age group (18–24, 25–34, 35–64), gender, and MHCP insurance program (Medicaid or 
MinnesotaCare). Medicaid is reserved for very low-income residents, whereas 
MinnesotaCare serves people at higher incomes that are still near the poverty threshold. 
Using data obtained from MHCP insurance claims during a 2-year period prior to study 
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initiation, ICD-9 codes consistent with diagnoses of schizophrenic disorders, psychotic 
disorder, bipolar I and II disorder, and/or major depressive disorder were used to 
categorize participants as having SMI (n=1044) or not having SMI (n=1277). 
Measures 
Measures were obtained from OPTIN baseline and follow-up survey data, as well as from 
MHCP administrative and claims data. 
Demographics 
Insurance program, age, sex, education, employment status, income, and race/ethnicity 
were assessed.  
Mental Health Diagnoses 
Participants with at least one ICD-9 code in the range of 1) 295.00 to 295.94 were 
considered to have a schizophrenic disorder, 2) 297.00 to 298.9 were considered to have 
a psychotic disorder, 3) 296.2 to 296.36 were considered to have a major depressive 
disorder, 4) 296.00 to 296.13 and/or 296.4 to 296.9 were considered to have a bipolar 
disorder. 
Smoking History 
Questions from the California Tobacco Survey62 and the Behavioral Risk Factor 
Surveillance System (BRFSS)63 were used to assess lifetime duration of smoking, time 
until first cigarette after waking, cigarettes smoked per day (CPD), and past year quit 
attempts. 
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Social Environment 
A composite variable was created to measure participants’ perceived social support for 
cessation by taking the mean of two support-related variables that assessed perceived 
support for quitting and others’ desire for quitting, respectively.28 These items were 
assessed on a 5-point scale, with higher scores indicating greater levels of support. 
Participants reported the proportion of their close friends and family who were smokers. 
Participants also indicated whether they lived with a child under the age of 18, whether 
they lived with another smoker, and the smoking rules within their home. 
Healthcare Provider Factors 
Healthcare Effectiveness Data and Information Set (HEDIS) tobacco performance 
measures were used to assess participants’ past year healthcare experiences.26 Items 
assessed whether participants received physician-delivered advice to quit, advice to use 
cessation medications, and advice to use ways (besides products) to help with quitting. A 
composite variable of perceptions of healthcare provider bias was created by summing 3 
items from the Physician Bias and Interpersonal Cultural Competence Measures Scale27 
(see Appendix). Each item was assessed on a 5-point scale, with higher values indicating 
greater perceptions of physician bias. Analyses run on the summary measure created for 
these items yielded an unadjusted Cronbach’s alpha reliability score of 0.74. 
Cessation Beliefs
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Self-efficacy for quitting was measured on a scale from 1 to 10, with higher values 
indicating greater confidence in quitting.28 The Contemplation Ladder assessed readiness 
to quit on a scale from 1 to 10, with higher values indicating greater readiness to quit.29 
Cessation Treatment Utilization 
Several items assessed whether participants used NRT products, prescription cessation 
medications, and behavioral counselling in the past year. 
Statistical Analysis 
Bivariate Analyses 
Bivariate analyses, using t-tests and Pearson’s chi-square tests, were used to compare 
participants with SMI to those without SMI across a series of socio-demographic, 
smoking history, cessation treatment utilization, healthcare provider, social environment, 
and cessation beliefs measures.  
Mediation Approach 
Mediation analyses adhered to the counterfactual approach, which asserts that the total 
effect of the exposure (SMI) on the outcome (cessation treatment utilization) can be 
decomposed into natural direct effects and natural indirect effects, or meditational 
effects.64 The direct effect is the amount of change that would occur in cessation 
treatment utilization in the presence vs. the absence of SMI, provided that for each 
individual the mediator (physician advice or physician bias, respectively) was kept at the 
level that it would have if each individual did not have SMI. The indirect effect expresses 
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how much the outcome would change on average if SMI was present, but the mediator 
was changed from the level it would have in the presence compared to the absence of 
SMI.  
This approach to effect decomposition was preferred over the conventional regression 
adjustment approach,65 which may produce biased effect estimates.64 A SAS macro 
developed by Valeri and VanderWheele utilizes the G-estimation approach and produces 
reliable effect estimates when using continuous, dichotomous, and/or count data.66 
Furthermore, these models produce reliable estimates even in the presence of an 
exposure/mediator interaction. 
Mediation Analyses 
Analyses will assess whether baseline measures of 1) physician-delivered advice to use 
medications (NRT and/or prescription) 2) physician-delivered advice to use other 
cessation treatments (not medications), and 3) participants’ perceptions of physician bias, 
separately, mediate the effect of SMI diagnosis on cessation treatment utilization at 12-
month follow-up (see Figure 1). The physician-delivered advice to use medications 
mediator was paired with 1) utilization of medications, and 2) utilization of any cessation 
treatment. The physician-delivered advice to use other cessation treatments mediator was 
paired with 1) utilization of counseling, and 2) utilization of any cessation treatment. The 
perceptions of physician bias mediator was paired with utilization of any cessation 
treatment. 
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Figure 1. Mediation Models and Timeline of Measures. 
 
 
 
 
 
 
 
 
 
 
Five hundred bootstrap samples were produced for each set of regression analyses from 
which effect estimates and their associated confidence intervals were derived. In 
modeling the dichotomous outcome variables (cessation treatment use vs. none), Poisson 
regressions were fit to the data in order to produce relative risk (RR) estimates. Poisson 
regression was chosen due to the well-documented problems with utilizing logistic 
regression with common dichotomous outcomes (over 10% prevalence),66,67 and due to 
its superiority for model convergence relative to binomial models. Logistic regressions 
modeled the physician advice mediators (medications and other) and linear regressions 
modeled the perceptions of physician bias mediator.  
Model Building 
Prior to model building, each exposure/mediator pairing was evaluated for statistical 
interaction in their effects on a given outcome. None of the pairings produced statistically 
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significant interactions; thus, interaction terms were not included in any of the following 
analyses. 
In order to produce valid effect estimates, counterfactual mediation models assume no 
unmeasured or uncontrolled confounding between the 1) exposure and outcome, 2) 
exposure and the mediator, and 3) mediator and the outcome.  
For each mediator/outcome pairing, a series of mediation analyses were conducted 
beginning with a minimally-adjusted model controlling only for intervention condition 
(proactive outreach vs. usual care). Sequential adjustments for blocks of socio-
demographic (insurance program, age, gender, race/ethnicity, employment, education, 
income), smoking history (time until first cigarette after waking, CPD), and social 
environment (proportion of close friends/family that smoke, social support for quitting, 
and home smoking rules) variables were then performed.  
Sensitivity Analyses 
In order to elucidate the association between SMI and cessation treatment utilization, 
Poisson regressions were used to examine the effect of SMI on cessation treatment 
utilization (medication, counseling, any form) while statistically adjusting for clinical 
encounter frequency.  
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Results 
Baseline Comparison of Smokers with SMI vs without SMI  
Compared to non-SMI smokers (n=1277), those with SMI (n=1044) were more likely to 
be enrolled in Medicaid, were older, and were more likely to be female. Few differences 
emerged across race and ethnicity, although there were slightly greater proportions of 
Black and American Indian participants among those with SMI. Smokers with SMI also 
had lower educational attainment, were much more likely to report being unable to work 
or disabled, and earned less than their non-SMI counterparts; factors that are consistent 
with heightened rates of enrollment in Medicaid rather than MinnesotaCare (see Table 3). 
Participants with SMI smoked more cigarettes per day, had smoked for a greater number 
of years, and were more likely to report smoking within 5 minutes of waking. Smokers 
with and without SMI had similar rates of past year quit attempts, but those with SMI 
utilized cessation treatments at much higher rates. 
Smokers with SMI had greater proportions of family/friends that were current smokers, 
had less restrictive home smoking rules, but had similar levels of social support for 
quitting compared to smokers without SMI. 
Although smokers with SMI had significantly lower self-efficacy for quitting, they did 
not differ from smokers without SMI with respect to readiness to quit.  
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Table 3. Baseline Demographic, Smoking History, Social Environment, Healthcare 
Provider, and Cessation Belief Characteristics of SMI vs Non-SMI Smokers 
 
Characteristic 
SMI 
N=1044 
Non-SMI 
N=1277 
 
p Value 
 No. (%) or Mean±SD  
Demographics    
Insurance Program    
    Medicaid 861 (82.5) 813 (63.7) <0.001 
    MnCare 183 (17.5) 464 (36.3) . 
Age    
18-24 172 (16.5) 279 (21.9) <0.001 
25-34 344 (33.0) 459 (35.9) . 
35-64 528 (50.6) 539 (42.2) . 
Male 274 (26.3) 412 (32.3) 0.002 
Race/Ethnicity    
White 801 (76.7) 1012 (79.3) 0.078 
Black or African American 130 (12.5) 122 (9.6) . 
Amer Indian or Alaskan Native 79 (7.6) 84 (6.6) . 
Hispanic or Latino 15 (1.4) 27 (2.1) . 
Asian or Pacific Islander 19 (1.8) 32 (2.5) . 
Education    
Grade 11/lower                                                                                                                                                                                                                                                                        161 (15.8) 157 (12.6) 0.001
HS grad/GED 344 (33.8) 418 (33.4) . 
Some college 428 (42.0) 513 (41.0) . 
College grad/higher 85 (8.4) 163 (13.0) . 
Employment     
Employed/self-employed 352 (34.4) 789 (63.0) <0.001 
Student 86 (8.4) 72 (5.8) . 
Out of work 161 (15.7) 138 (11.0) . 
Unable to work/disabled 370 (67.6) 177 (14.1) . 
Homemaker 54 (5.3) 77 (6.2) . 
Yearly income    
Less than $10k 488 (48.8) 350 (28.8) <0.001 
$10,001-$20k 295 (29.5) 403 (33.2) . 
$20,001-$40k 157 (15.7) 312 (25.7) . 
More than $40k 61 (6.1) 150 (12.4) . 
Smoking History    
Cigs/day 14.7±9.6 13.0±8.8 <0.0011 
Duration (yrs) 21.7±12.9 19.7±13.0 <0.001 
Time until 1st cig (mins)    
≤ 5 321 (31.1) 285 (22.6) <0.001 
6 – 15 332 (32.1) 348 (27.6) . 
16 – 30 157 (15.2) 185 (14.7) . 
31 – 60 100 (9.7) 169 (13.4) . 
> 60 123 (11.9) 274 (21.7) . 
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1Satterthwaite test 
 
SMI and Cessation Treatment Utilization 
In unadjusted analyses, SMI was positively associated with cessation treatment utilization 
(medications, counseling, and any form) at 12-month follow-up (Table 4). 
 
 
 
Past year quit attempt 565 (55.1) 677 (53.8) 0.536 
Any treatment used 411 (39.4) 328 (25.7) <0.001 
Social Support    
Support of others for quitting  4.4±0.8 4.4±0.7 0.1021 
Social Norms    
Friends/family who smoke    
Almost all 258 (24.9) 221 (17.4) <0.001 
Over half 230 (22.2) 267 (21.1) . 
About half 235 (22.7) 363 (28.7) . 
Less than half 139 (13.4) 199 (15.7) . 
Very few 151 (14.6) 193 (15.2) . 
None 23 (2.2) 24 (1.9)  
Home smoking rules    
Smoking is not allowed 471 (45.4) 681 (53.8) <0.001 
Smoking is allowed at times 276 (26.6) 333 (26.3) . 
Smoking is allowed 291 (28.0) 253 (20.0) . 
Healthcare Provider    
Regular physician 857 (83.6) 900 (71.6) <0.001 
Physician advised to quit 748 (79.0) 811 (74.5) 0.017 
Physician discussed medications 428 (45.5) 438 (40.4) 0.022 
Physician discussed other  494 (52.5) 466 (42.9) <0.001 
Physician bias 5.9±2.9 5.8±2.8 0.475 
Clinical transactions 252.5±304.1 78.8.9±126.2 <0.001 
Cessation Beliefs    
Quitting self-efficacy 4.7±3.0 5.3±3.1 <0.001 
Contemplation Ladder 6.3±2.9 6.3±2.9 0.495 
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Table 4. Cessation Treatment Utilization of SMI vs Non-SMI Smokers at 12-Month 
Follow-up 
 
Associations Between Mediators 
Advice to use cessation medications was positively associated with advice to use other 
forms of cessation treatments (p<0.001) (see Table 5). Both treatment advice mediators 
were negatively associated with perceptions of physician bias (all p<0.001). 
Table 5. Correlation Across Mediators 
 
* = p<0.001 
 
Summary of Regression Effects 
Physician Advice to Use Medications 
In a logistic regression controlling for intervention condition, SMI was positively 
associated with physician advice to use cessation medications (β1=0.49, OR=1.63, 
p<0.001). In a Poisson regression controlling for intervention condition, physician advice 
to use cessation medications was positively associated with use of cessation medications 
 
Outcome 
SMI 
N=761 
Non-SMI 
N=947 
 
p Value 
 No. (%)  
Treatment Utilization    
Medications 319 (41.9) 282 (29.8) <0.001 
Counseling  109 (14.3) 105 (11.1) 0.045 
Any 340 (44.7) 299 (31.6) <0.001 
Mediator 
Medication 
Advice 
Other 
Advice 
Physician 
Bias 
Medication Advice - - - 
Other Advice 0.640* - - 
Physician Bias  -0.171* -0.165* - 
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(β2=0.42, RR=1.53, p<0.001) (Figure 2) and any form of cessation treatment (β3=0.38, 
RR=1.45, p<0.001) (Figure 3).   
Figure 2. Summary of Effects for Physician Advice to Use Medication Mediator and 
Medication Use Outcome 
 
 
 
   * = p<0.001 
 
Figure 3. Summary of Effects for Physician Advice to Use Medication Mediator and 
Any Treatment Use Outcome  
 
 
 
   * = p<0.001 
 
Physician Advice to Use Other 
In a logistic regression controlling for intervention condition, SMI was positively 
associated with physician advice to use cessation treatments other than medications 
(β1=0.31, OR=1.37, p<0.001). In a Poisson regression controlling for intervention 
condition, physician advice to use treatments other than medications was positively 
associated with use of cessation counseling (β2=0.24, RR=1.27, p=0.087) (Figure 4) and 
any form of cessation treatment (β3=0.29, RR=1.34, p<0.001) (Figure 5). 
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Figure 4. Summary of Effects for Physician Advice to Use Other Treatments Mediator 
and Counseling Use Outcome  
 
 
 
* = p<0.001 
 
Figure 5. Summary of Effects for Physician Advice to Use Other Treatments Mediator 
and Any Treatment Use Outcome 
 
 
 
* = p<0.001 
 
Perceptions of Physician Bias 
In a linear regression controlling for intervention condition, SMI was not associated with 
perceptions of physician bias advice (β1=0.09, p=0.454). In a Poisson regression 
controlling for intervention condition, physician bias was not associated with the use of 
any form of cessation treatment (β2=-0.004, p=0.798) (Figure 6). 
Figure 6. Summary of Effects for Perception of Physician Bias Advice Mediator and 
Any Treatment Use Outcome 
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Meditation Effects 
There was a significant total effect of SMI on cessation treatment utilization (medications 
and any treatment use) at 12-month follow-up across all models (see Table 6). 
Physician Advice to Use Medications 
Across all the models predicting utilization of medications and utilization of any form of 
cessation treatment, the indirect effects were small but statistically significant. In the 
models controlling only for intervention condition, the proportion of the total effect of 
SMI on smoking cessation treatment utilization that was mediated by the effect of SMI 
on physician advice to use medications was 13.4% for medication utilization and 11.7% 
for any treatment utilization. The directions of these effects were positive and indicate 
partial mediation. Mediation effects were attenuated in subsequent models controlling for 
blocks of demographic, smoking history, and social environment covariates, but 
remained statistically significant (see Table 6). 
Physician Advice to Use Other Treatments 
SMI was positively associated with utilization of cessation counseling at 12-month 
follow-up, although the total effects did not reach statistical significance (see Table 6). 
The indirect effect was statistically significant in the model predicting utilization of 
cessation counseling, controlling only for intervention condition. The indirect effects did 
not reach statistical significance in the more fully adjusted models. Across the first three 
models predicting any cessation treatment utilization, the indirect effects were small but 
statistically significant. In the model controlling only for intervention condition, the 
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proportion of the total effect of SMI on any cessation treatment utilization that was 
mediated by the effect of SMI on physician advice to use other treatments was 6.0%. The 
directions of these effects were positive and indicate partial mediation. Mediation effects 
were attenuated in more fully adjusted models, but remained statistically significant. 
Perceptions of Physician Bias  
The indirect effects were not statistically significant in any of the models predicting any 
treatment use, indicating no mediation by perceptions of physician bias (see Table 6)
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      Table 6. Mediation Effects for Physician Advice and Physician Bias Mediators and Treatment Utilization Outcomes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     Model 1 is adjusted for intervention condition 
     Model 2 is adjusted for intervention condition and demographics 
     Model 3 is adjusted for intervention condition, demographics, and smoking history 
     Model 4 is adjusted for intervention condition, demographics, smoking history, and social environment
 
Mediator 
 
Outcome 
 
Model 
Total Effect 
RR (95% CI) 
Direct Effect 
RR (95% CI) 
Indirect Effect 
RR (95% CI) 
Proportion 
Mediated (%) 
Physician 
Advice to Use 
Medication 
Medication use 
Model 1 
Model 2 
Model 3 
Model 4 
1.41 (1.24-1.60) 
1.30 (1.14-1.50) 
1.23 (1.07-1.43) 
1.23 (1.07-1.40) 
1.34 (1.19-1.53) 
1.26 (1.10-1.45) 
1.20 (1.05-1.39) 
1.20 (1.05-1.36) 
1.05 (1.03-1.07) 
1.03 (1.02-1.06) 
1.02 (1.01-1.05) 
1.02 (1.01-1.04) 
13.4 
12.6 
11.1 
10.3 
Any treatment 
use 
Model 1 
Model 2 
Model 3 
Model 4 
1.41 (1.26-1.57) 
1.28 (1.12-1.46) 
1.23 (1.06-1.41) 
1.21 (1.06-1.39) 
1.35 (1.21-1.51) 
1.24 (1.09-1.42) 
1.20 (1.05-1.38) 
1.19 (1.04-1.37) 
1.04 (1.02-1.06) 
1.03 (1.01-1.05) 
1.02 (1.01-1.04) 
1.02 (1.01-1.03) 
11.7 
11.4 
9.5 
8.6 
Physician 
Advice to Use 
Other 
Counseling use 
Model 1 
Model 2 
Model 3 
Model 4 
1.26 (0.95-1.62) 
1.16 (0.85-1.50) 
1.07 (0.81-1.42) 
1.10 (0.83-1.41) 
1.24 (0.94-1.60) 
1.15 (0.85-1.48) 
1.06 (0.81-1.41) 
1.09 (0.82-1.41) 
1.02 (1.00-1.05) 
1.01 (0.99-1.03) 
1.01 (0.99-1.03) 
1.01 (0.99-1.03) 
7.9 
8.8 
11.4 
6.9 
Any treatment 
use 
Model 1 
Model 2 
Model 3 
Model 4 
1.41 (1.24-1.60) 
1.29 (1.14-1.47) 
1.23 (1.08-1.38) 
1.22 (1.06-1.41) 
1.38 (1.22-1.57) 
1.27 (1.12-1.44) 
1.22 (1.06-1.37) 
1.21 (1.05-1.40) 
1.02 (1.01-1.04) 
1.02 (1.00-1.03) 
1.01 (1.00-1.02) 
1.01 (0.99-1.02) 
6.0 
6.0 
4.8 
4.1 
Perceived 
Physician Bias 
Any treatment 
use 
Model 1 
Model 2 
Model 3 
Model 4 
1.43 (1.26-1.60) 
1.30 (1.14-1.49) 
1.25 (1.08-1.43) 
1.23 (1.09-1.40) 
1.42 (1.26-1.60) 
1.30 (1.14-1.49) 
1.25 (1.08-1.43) 
1.23 (1.09-1.40) 
0.99 (0.99-1.00) 
0.99 (0.99-1.00) 
1.00 (0.99-1.00) 
0.99 (0.99-1.00) 
0.1 
0.0 
0.0 
0.0 
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Sensitivity Analysis  
SMI, Cessation Treatment Utilization, and Clinical Encounter Frequency 
Compared to unadjusted models, regression models adjusting for clinical encounter 
frequency resulted in attenuated effects of SMI on cessation treatment utilization 
(medication, counseling, and any form) (see Table 7). 
Table 7. Cessation Treatment Utilization of SMI vs Non-SMI Smokers at 12-Month 
Follow-up Adjusting for Clinical Encounters 
+ Adjusted for clinical encounter frequency 
 
Discussion 
This is one of the first studies to explore rates of cessation treatment utilization among 
smokers with MH disorders, and is the first to examine cessation treatment utilization 
within a sample of socioeconomically disadvantaged smokers with recent diagnoses that 
are consistent with SMI. Contrary to our hypothesis, smokers with SMI utilized cessation 
treatments at higher rates than smokers without SMI. These results were partially 
Outcome 
SMI 
N=761 
Non-SMI 
N=947 
Relative Risk 
(95% CI) 
 
p Value 
 (No.) %   
Medication Use      
Min adjusted 319 (41.9) 282 (29.8) 1.39 (1.19-1.64) <0.001 
Fully adjusted - - 1.26 (1.05-1.51) 0.013 
Fully adjusted+   1.23 (1.02-1.48) 0.030 
Counseling Use      
Min adjusted 109 (14.3) 105 (11.1) 1.24 (0.94-1.62) 0.112 
Fully adjusted - - 1.07 (0.79-1.45) 0.644 
Fully adjusted+   0.98 (0.71-1.34) 0.890 
Any Treatment Use      
Min adjusted 340 (44.7) 299 (31.6) 1.40 (1.20-1.63) <0.001 
Fully adjusted - - 1.25 (1.05-1.49) 0.013 
Fully adjusted+   1.21 (1.01-1.45) 0.037 
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explained by socio-demographic, smoking history, and social environment confounders, 
as well as a heightened frequency of clinical contact among smokers with SMI.  
The primary goal of the present study was to elucidate the smoking cessation process 
among smokers with SMI by exploring how healthcare provider interactions influence 
cessation treatment utilization within this population. Past literature indicated that 
smokers with SMI would be less likely to report receiving physician-delivered advice to 
use cessation treatments and would be more likely to perceive physician bias. However, 
our results show that smokers with SMI received higher rates of physician-delivered 
advice to use cessation treatments, effects which were associated with higher rates of 
cessation treatment utilization. Smokers with SMI also reported approximately equivalent 
levels of physician bias compared to smokers without SMI, and physician bias was not 
significantly associated with cessation treatment utilization.  
The meditational effects of physician advice to use cessation treatments were small, but 
they highlight the role that healthcare providers play in the cessation process. Physician 
advice to use medications was positively associated with both medication utilization and 
any form of cessation treatment utilization. These results indicate that baseline advice to 
use a specific type of cessation product was associated with the use of that product 12 
months later, suggesting that physician explanations regarding the benefits of cessation 
medications and how to properly use them may spur action on the part of the patient. 
These results also suggest a sort of carry-over effect of providing advice to use a specific 
cessation product, as advice to use medications had a similarly large effect on the use of 
any form of cessation treatment. It may be the case that discussing specific cessation 
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strategies with a patient may act as a sort of primer for the use of other cessation 
treatments, as participants who utilize one form of treatment may be more willing to try 
other treatments in the future.  
Physician advice to use other forms of cessation treatment besides medications (including 
counseling) was not significantly associated with the use of counseling at 12-month 
follow-up, although these effects did trend in a positive direction. It is possible that a lack 
of an effect was due to the more broad nature of this physician advice measure, which 
could refer to forms of treatment other than just counseling (e.g. peer support groups, 
internet cessation resources, etc.). However, advice to use other forms of treatment was 
significantly associated with the use of any form of cessation treatment, again providing 
evidence for a carry-over effect of more specific cessation advice on an increased 
willingness to use any cessation treatment.  
Smokers with SMI were not more likely to perceive physician bias than those without 
SMI. It is possible that, because the vast majority of participants with SMI (nearly 84%) 
reported having a regular physician, these patients may have felt more comfortable with 
their healthcare providers due to increased frequency of contact. In addition, this measure 
focused on patients’ perceptions of physician bias. As such, even if some physicians’ 
hold more discriminatory beliefs toward patients with SMI, this may not be expressed in 
an overt way that is perceived by the patient.  
Our results also indicate a lack of an association between baseline perceptions of 
physician bias and cessation treatment utilization at 12-months. However, it is important 
to note that there was a negative correlation between perceptions of physician bias and 
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physician-delivered advice to use medications and to use other forms of treatment. Thus, 
although patients’ perceptions of physician bias do not appear to influence patients’ use 
of cessation treatments, these perceptions are associated with differential cessation care. 
In light of the strong positive association between SMI and treatment utilization, 
sensitivity analyses were performed to explore whether these finding were influenced by 
frequency of clinical contact. Indeed, our results indicate that smokers with SMI had far 
more clinical encounters in the 2-year period prior to study initiation than smokers 
without SMI. Furthermore, when the frequency of clinical encounters was added as a 
potential confounder in regression models predicting treatment utilization, the positive 
association between SMI and treatment utilization was attenuated. This suggests that SMI 
smokers’ comparatively high rates of cessation treatment utilization are at least partially 
explained by the heightened frequency with which they interact with their healthcare 
providers.  
Limitations 
Although the timeline of assessments establishes temporality across the measures, a key 
assumption of our analytic plan is that of causal effects between the exposure, mediator, 
and outcome. There is a case to be made for casualty given the body of literature 
supporting strong links between these factors, even though the investigators did not 
assign the exposure variable. Because these data were analyzed as observational there is 
also the potential for unmeasured confounding to bias our effect estimates. We were also 
unable to obtain measures of functional impairment to pair with the MH diagnoses 
obtained from the DHS claims data. Functional assessments would increase the 
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likelihood that the smokers included in our SMI category were experiencing a high 
degree of current life impairment; an important diagnostic criterion for assessing SMI. 
Conclusion 
The strong positive association between physician-delivered advice to use cessation 
treatments and cessation treatment utilization, among smokers with and without SMI, 
highlights the important role that healthcare providers play in the cessation process. 
Because our sample of smokers were enrolled in MHCP and had access to free or 
reduced cost healthcare, it is difficult to extend these findings to the broader population 
of smokers who may have more variable access to healthcare. However, the high rates of 
physician-delivered cessation advice reported by this sample suggest that the expansion 
of publicly-subsidized insurance programs may result in greater rates of treatment 
utilization among low-income smokers. Smokers with SMI were more likely to use 
cessation treatments than those without SMI, but this group still experiences heightened 
rates of smoking relative to the general population. Indeed, evidence suggests that 
smokers with SMI require a greater number of quit attempts and may need to utilize a 
greater number of treatment strategies before achieving cessation. As such, findings ways 
to bolster rates of physician contact and engagement is particularly important for this 
group.68 Given the time limitations faced by physicians, strategies to address this issue 
may involve having systems in place to efficiently provide these smokers with referrals 
for external cessation resources. Going forward, it is critical that we provide smokers 
with MH disorders with the professional support they need in order to achieve long-term 
abstinence, and ultimately eliminate this health disparity.  
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Research Study 2 
Title: Effectiveness of a proactive outreach smoking cessation intervention among 
socioeconomically disadvantaged smokers:  
The role of serious mental illness 
Specific Aims 
Aim 1: To examine the effect of a proactive outreach intervention on cessation treatment 
utilization and prolonged abstinence among smokers with SMI and without SMI.  
Hypothesis 1(i): The proactive outreach intervention will be effective for 
promoting cessation treatment utilization among smokers with SMI and without 
SMI.  
Hypothesis 1(ii): The proactive outreach intervention will be effective for 
promoting prolonged abstinence among smokers with SMI and without SMI.  
Exploratory Aim: To examine whether a proactive outreach intervention is significantly 
more effective, with respective to cessation treatment utilization and prolonged 
abstinence, for smokers with SMI compared to those without SMI. 
Hypothesis(i): The proactive outreach intervention will be significantly more 
effective for increasing cessation treatment utilization for smokers with SMI 
relative to those without SMI. 
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Hypothesis(ii): The proactive cessation intervention will be significantly more 
effective for promoting smoking abstinence among smokers with SMI relative to 
those without SMI. 
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Abstract 
Introduction 
Despite overall declines in smoking prevalence, significant socioeconomic and mental 
health disparities remain. The purpose of the present study is to examine whether a 
proactive outreach intervention that facilitated access to cessation treatments and 
addressed smokers’ psychosocial needs was effective for promoting cessation treatment 
utilization and prolonged abstinence among low-income smokers with SMI.  
Methods 
Data were taken from the OPTIN study. The intervention included mailings, telephone 
outreach, counseling, and access to free cessation treatments. ICD-9 codes indicating 
diagnoses of schizophrenic disorders, psychotic disorder, bipolar disorders, and major 
depressive disorder were used to categorize participants in SMI (n=1044) or non-SMI 
(n=1277) groups. Logistic regressions modelled the effect of the intervention on 
cessation treatment utilization (medication, counseling, any form) and 6-month prolonged 
abstinence at 12-month follow-up in the SMI and non-SMI groups, respectively. Logistic 
regressions then tested for the presence of intervention x SMI interactions on all 
outcomes. 
Results 
Relative to usual care, the intervention increased any form of treatment utilization in the 
SMI group (51.6% vs 38.1%, p<0.001) and the non-SMI group (38.6% vs 25.8%, 
p<0.001). The intervention also increased prolonged abstinence in the SMI group (14.7% 
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vs 10.8%, p=0.070) and the non-SMI group (18.1% vs 12.8%, p=0.019). There were no 
interactions between the intervention and SMI on any of the outcomes tested. 
Discussion 
Results suggest that proactive outreach is a promising strategy for boosting cessation 
treatment utilization and abstinence rates among smokers enrolled in publicly-subsidized 
state insurance programs. This is particularly important for smokers with SMI, who tend 
to engage in a greater number of quit attempts and utilize more treatments before 
achieving cessation. 
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Introduction 
Population-level declines in the prevalence of smoking have given rise to significant 
socioeconomic and mental health disparities in smoking rates. While the prevalence of 
smoking among those with private insurance is 15%,3 close to 30% of the medically 
uninsured and Medicaid enrollees are current smokers. The prevalence of smoking 
among those with mental health disorders is also exceedingly high, ranging from two to 
three times higher than that of the general US population depending on clinical 
diagnosis.8 As socioeconomic disadvantage is associated with an increased likelihood of 
having a mental health disorder, socioeconomically disadvantaged smokers with SMI 
need to be a focal point of cessation efforts going forward. 
Smokers with SMI face barriers to cessation at multiple levels of influence, contributing 
to the persistent high rates of smoking experienced by this population. At the individual 
level, the “self-medication” hypothesis posits that individuals with mental illness smoke 
to reduce the experience of negative affect and anxiety associated with their 
condition,47,48 factors which could reduce the likelihood of engaging in a quit attempt. 
Smokers with SMI also experience heightened nicotine withdrawal symptoms when 
trying to quit, including depressed mood, generalized discomfort, and anxiety.49,50 With 
respect to cessation beliefs, smokers with SMI have low self-efficacy for quitting35,51,52 
but tend to be highly motivated to quit.69 
At the interpersonal level, smokers with SMI are more likely to have peers that are 
accepting of smoking and view tobacco use as a normative behavior.35 In addition, 
individuals with SMI may be more susceptible to peer influence regarding smoking 
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behavior, as a study of adolescents demonstrated that more severe symptoms of 
depression were associated with greater peer acceptability of smoking.36 The social 
acceptability of smoking is especially pervasive in in-patient mental health settings. 
Indeed, smoking has historically been encouraged within psychiatric units35,36 and has 
been used as a reward to reinforce certain behaviors among these patients.53  
At the healthcare provider level, evidence suggests that smokers with SMI may receive 
differential cessation-related care from their physicians. Healthcare professionals may 
discourage quitting for these patients due to a belief that this may exacerbate their 
depressive symptoms.37,38 Physicians also face many competing treatment demands for 
those with SMI.38,39 This “treatment overshadowing”, in which a physician prioritizes the 
treatment of MH symptoms over other health concerns,40 may contribute to lower rates of 
cessation-related care for this group.  
The OPTIN trial organized these barriers in a conceptual framework that was informed 
by elements of Social Cognitive Theory (SCT),5,6 the Transtheoretical (Stages of Change) 
Model,7 and the Biopsychosocial Model of Perceived Discrimination.8 While the original 
framework was tailored to the low-income OPTIN sample, the present study adapts this 
framework to reflect the barriers experienced by low-income smokers with co-occurring 
SMI. The SCT component helps elucidate the roles that social acceptance of smoking and 
low self-efficacy for quitting may have on cessation treatment utilization among low-
income smokers with SMI. The Transtheoretical Model, which asserts 5 distinct phases 
of behavior change, provides a framework for smokers’ progression through the phases 
of treatment utilization, cessation initiation, and prolonged abstinence, and how 
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individual, interpersonal, and healthcare provider barriers can interfere with this 
progression. The Biopsychosocial Model of Perceived Discrimination helps delineate the 
influence of discrimination in social or healthcare settings on the utilization of cessation 
treatments and prolonged abstinence; barriers that may be exacerbated for smokers with 
SMI.  
The OPTIN trial sought to address these barriers to cessation treatment utilization and 
abstinence by implementing a proactive outreach cessation intervention. Proactive 
outreach strategies, which promote heightened contact with smokers, facilitate access to 
cessation treatments, and provide motivational quit advice while promoting self-efficacy, 
may be an effective approach for minimizing barriers to treatment utilization and 
abstinence among smokers with SMI. With respect to psychosocial barriers, the outreach 
and motivational interviewing components of the intervention are designed to improve 
smokers’ self-efficacy for quitting and address social environmental barriers like 
permissive social norms and low social support for quitting. By facilitating access to 
evidence-based cessation resources, proactive outreach can address the healthcare 
provider barriers of competing treatment demands, the perception that smokers with SMI 
are not motivated to quit, and low rates of referral for cessation services.  
The aim of the present study is to examine the effectiveness of a proactive outreach 
intervention among socioeconomically disadvantaged smokers with SMI and without 
SMI, with respect to rates of cessation treatment utilization and 6-month prolonged 
abstinence at 12-month follow-up. Because components of proactive outreach are 
hypothesized to overcome cessation treatment utilization barriers that may be exacerbated 
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for smokers with SMI, an exploratory aim is to examine whether the intervention is 
significantly more effective for smokers with SMI relative to those without SMI. 
Methods 
Study Design 
Data were obtained from the OPTIN study (N=2406); a two-arm RCT which evaluated 
the effect of proactive outreach on rates of 6-month prolonged abstinence in a sample of 
smokers enrolled in MHCP.70 The study sample was stratified by age group (18–24, 25–
34, 35–64), gender (male or female), and insurance program (Medicaid or 
MinnesotaCare). Using MHCP insurance claims drawn from a 2-year period prior to 
study initiation, ICD-9 codes indicative of schizophrenic disorders, psychotic disorder, 
bipolar I and II disorder, and/or major depressive disorder were used to categorize 
participants as having SMI (n=1044) or not having SMI (n=1277). 
Measures 
Measures were obtained from OPTIN baseline and follow-up survey data, as well as from 
MHCP administrative and claims data. 
Demographics 
Insurance program, age, sex, race/ethnicity, education, employment status, and income 
were assessed. 
Mental Health Diagnoses 
Participants with at least one diagnostic code in the range of 1) 295.00 to 295.94 were 
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considered to have a schizophrenic disorder, 2) 297.00 to 298.9 were considered to have 
a psychotic disorder, 3) 296.2 to 296.36 were considered to have a major depressive 
disorder, 4) 296.00 to 296.13 and/or 296.4 to 296.9 were considered to have a bipolar 
disorder. 
Smoking History 
Questions from the California Tobacco Survey 62 and the BRFSS63 were used to assess 
lifetime duration of smoking, time until first cigarette after waking, cigarettes smoked per 
day, and past year quit attempts. 
Social Environment 
A composite variable measured participants’ perceived social support for cessation by 
taking the mean of two support-related variables that assessed perceived support for 
quitting and others’ desire for quitting, respectively.28 All items were assessed on a 5-
point scale, with higher scores indicative of greater levels of social support. Participants 
reported the proportion of their close friends and family who were smokers. Participants 
then reported whether they lived with a child under the age of 18, whether they lived with 
another smoker, and the smoking rules within their home. 
Healthcare Provider Factors 
HEDIS tobacco performance measures were used to assess participants’ past year 
healthcare experiences.26 Items assessed whether participants received physician-
delivered advice to quit, advice to use cessation medications, and advice to use ways 
(besides products) to help with quitting. A composite variable of perceptions of 
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healthcare provider bias was created by summing 3 items from the Physician Bias and 
Interpersonal Cultural Competence Measures Scale.27 Each item was assessed on a 5-
point scale, with higher values indicating greater perceptions of physician bias.  
Cessation Beliefs 
Self-efficacy for quitting was measured on a 1 to 10 scale, with higher values indicating 
greater confidence in quitting.28 The Contemplation Ladder assessed readiness to quit on 
a 1 to 10 scale, with higher values indicating a greater readiness to quit.29 
Outcomes 
Cessation Treatment Utilization 
Items assessed whether participants used NRT products, prescription cessation 
medications, and behavioral counselling in the past year at	12-month follow-up. These 
items were used to create dichotomized measures indicating the use of any medication, 
any counselling, and any form of treatment use. 
Smoking Abstinence  
A self-report measure was used to assess 6-month prolonged abstinence at 12-month 
follow-up.71 Participants who reported smoking at least once on 7 consecutive days or at 
least once on 2 consecutive weekends in the 6-month period prior to the follow-up survey 
were considered continuing smokers. 
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Conceptual Framework 
The conceptual framework guiding the proactive outreach intervention was informed by 
SCT,5,6 the Transtheoretical Model,7 and the Biopsychosocial Model of Perceived 
Discrimination. 8 SCT asserts that a complex interplay of individual (cognitive), social 
environment, and behavioral forces influence each other throughout the process of 
behavior change. In the context of smoking cessation among the socioeconomically 
disadvantaged, SCT emphasizes the roles that permissive social norms and low self-
efficacy for quitting may have on cessation treatment utilization. The Transtheoretical 
Model stipulates that as an individual undergoes a behavior change they pass through a 
series of cognitive stages including precontemplation, contemplation, preparation, action, 
and maintenance. With respect to smoking cessation, progression from the initiation of 
treatment utilization, adherence to cessation care, and maintenance of abstinence can be 
thought of as guided by these stages. The Biopsychosocial Model of Perceived 
Discrimination asserts that perceptions of discrimination, which socioeconomically 
disadvantaged smokers may experience in social or healthcare provider settings, 
influence their likelihood of engaging in a quit attempt and utilizing cessation treatments.  
Although the original conceptual framework was tailored to the low-income OPTIN 
sample, it can be argued that many of the barriers to cessation treatment experienced by 
these smokers are exacerbated for those with SMI. These smokers are likely to have peer 
networks that are more conducive to smoking, lower self-efficacy for quitting, and 
heightened perceptions of physician bias relative to their non-SMI counterparts. These 
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theorized links are reflected in the revised version of the original OPTIN conceptual 
framework (see Figure 7).
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Figure 7. Conceptual Framework Describing a Proactive Outreach Intervention for Smoking Cessation. 
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Proactive Outreach Intervention 
The intervention was designed to minimize psychosocial and healthcare provider barriers 
to cessation treatment utilization and abstinence, and contained two primary components. 
Outreach 
In the outreach component of the intervention, participants received “targeted” 
motivation materials in the form of mailed invitation materials and telephone contacts. 
The messaging was informed by focus groups and was designed to appeal to a low-
income population, as such messaging is more effective for stimulating interest in an 
intervention than generic messaging.72 The mailings provided motivational 
encouragement for smokers to seek out and use cessation treatments, as well as 
information regarding the safety and efficacy of the NRT products that would be 
provided to the participants. Several weeks after the outreach materials were mailed, 
participants were contacted via telephone. The outreach calls were meant to 1) provide 
motivational advice for quitting, 2) promote quitting self-efficacy, 3) encourage 
participants to utilize the provided cessation treatments, and 4) give information about 
how to properly use NRT. 
Access to Evidence-Based Cessation Treatment  
The intervention also facilitated access to free, comprehensive cessation treatments. An 
8-week course of NRT (patch, gum or lozenge) was mailed to participants prior to their 
target quit date. In addition, participants were offered intensive, telephone-based 
behavioral counseling. This counseling employed a motivational interviewing (MI) and 
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cognitive-behavioral approach to smoking cessation. MI techniques are appropriate for 
smokers at all levels of readiness to quit,73 and stress collaboration between the counselor 
and the participant..74 An adaptation of the California Helpline protocol was used to 
deliver the counseling,75 which consisted of 7 calls that were initiated by the counselor. 
Usual Care 
Participants in usual care had access to the existing care structure provided by MHCP. 
All MHCP enrollees have a primary care provider and may consult with this provider to 
receive cessation treatment. In this way, participants assigned to UC had access to similar 
treatment options as the intervention group, but they were not specifically invited to 
receive cessation treatment or provided with facilitated access to these treatments. 
Statistical Analysis 
Bivariate Analyses 
Using t-tests and Pearson’s chi-square we compared participants with SMI and without 
SMI participants across socio-demographic, smoking history, healthcare provider, social 
environment, cessation beliefs, cessation treatment utilization, and smoking abstinence 
measures.  
Main Effect of Intervention  
Logistic regressions modeled the effect of intervention condition (outreach vs. usual care) 
on cessation treatment utilization (medications, counseling, any form) and 6-month 
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prolonged abstinence at 12-month follow-up, controlling for the stratification variables of 
age, sex, and insurance program. 
Intervention Effect Stratified by SMI Group 
Logistic regressions, stratified by SMI group, modelled the effect of intervention 
condition on cessation treatment utilization and prolonged abstinence while controlling 
for the stratification variables. 
SMI x Intervention Interaction  
Primary Outcomes 
Logistic regressions modelled cessation treatment utilization and prolonged abstinence 
using intervention condition, SMI group, and an intervention by SMI interaction term as 
predictors. These models also controlled for the stratification variables.  
Missing Data 
In the regression models there was approximately 28% missing data for the SMI group 
and 27% missing data for the non-SMI group.  
Analyses were conducted to assess baseline differences between 12-month follow-up 
survey responders and non-responders. Regressions were run modeling the primary and 
secondary outcomes adjusting for variables that were associated with non-response to the 
12-month follow-up survey. 
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An iterative regression model process was then employed to impute 10 complete imputed 
versions of the baseline and 12-month follow-up survey data,76 which is considered 
sufficient for analyses of missing data.77 Regressions modeling the primary and 
secondary outcomes were run on the resulting datasets. Both minimally and fully 
adjusted models were included in these analyses. 
Results 
Missing Data 
With respect to demographic characteristics, survey non-responders were younger, were 
more likely to be non-White, were more poorly educated, and had lower annual income. 
In terms of smoking history, non-responders smoked for a shorter mean duration of time 
than responders and were more likely to report smoking their first cigarette more than one 
hour after waking. The groups were similar with respect to CPD, past year quit attempts, 
and use of cessation treatment at baseline (see Table 8). 
Non-responders had more smokers in their peer networks but were similar to responders 
in terms of home smoking rules. The groups had similar self-efficacy for quitting and 
readiness to quit. 
To control for these baseline differences, fully adjusted models adjusted for the variables 
of race/ethnicity, education, employment, income, duration of smoking, and time until 
first cigarette after waking. 
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Table 8. Characteristics of Follow-Up Survey Responders Vs. Non-Responders  
 
Characteristic 
 
Responder 
N=1770 
Non-
Responder 
N=636 
 
 
p Value 
 No. (%) or Mean  
Intervention    
Proactive outreach 826 (46.7) 374 (58.8) <0.001 
Usual care 944 (53.3) 262 (41.2) . 
Demographics    
Age    
18-24 316 (17.9) 180 (28.3) <0.001 
25-34 576 (32.5) 248 (39.0) . 
35-64 878 (49.6) 208 (32.7) . 
Male 511 (28.9) 195 (30.7) 0.395 
Race/Ethnicity    
White 1403 (79.3) 482 (75.8) 0.025 
Black or African American 188 (10.6) 68 (10.7) . 
Amer Indian or Alaskan Native 119 (6.7) 48 (7.6) . 
Hispanic or Latino 29 (1.6) 13 (2.0) . 
Asian or Pacific Islander 31 (1.8) 25 (3.9) . 
Education    
Grade 11/lower                                                                                                                                                                                                                                                                        197 (11.4) 125 (20.1) 0.003
HS grad/GED 563 (32.5) 218 (35.1) . 
Some college 755 (43.6) 22 (35.8) . 
College grad/higher 218 (12.6) 56 (9.0) . 
Employment     
Employed/self-employed 880 (50.5) 326 (52.7) 0.033 
Student 118 (6.8) 44 (7.1) . 
Out of work 211 (12.1) 96 (15.5) . 
Unable to work/disabled 433 (24.9) 120 (19.4) . 
Homemaker 100 (5.7) 33 (5.3) . 
Yearly income    
Less than $10k 611 (36.1) 437 (40.7) 0.034 
$10,001-$20k 556 (32.8) 164 (27.2) . 
$20,001-$40k 353 (20.9) 139 (23.0) . 
More than $40k 173 (10.2) 55 (9.1) . 
Mental Health    
SMI 761 (44.6) 283 (46.2) 0.492 
Smoking History    
Cigs/day 13.6 13.6 0.494 
Duration (yrs) 21.4 17.0 0.002 
Time until 1st cig (mins)    
≤ 5 344 (32.0) 273 (30.0) <0.001 
6 – 15 360 (33.5) 329 (25.3) . 
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Baseline Comparison of Smokers with SMI vs. without SMI  
Compared to non-SMI smokers (n=1277), those with SMI (n=1044) were more likely to 
be enrolled in Medicaid, tended to be older, and were more likely to be female. With 
respect to race and ethnicity, there were greater proportions of Black and American 
Indian participants in the SMI group. Smokers with SMI also tended to have lower 
educational attainment, were much more likely to report being unable to work or 
disabled, and earned significantly less than their non-SMI counterparts (see Table 9). 
In terms of smoking history, participants with SMI smoked significantly more cigarettes 
per day, had smoked for a greater number of years, and were more likely to report 
smoking within 5 minutes of waking. Although smokers with SMI and those without SMI 
16 – 30 166 (15.5) 190 (14.6) . 
31 – 60 90 (8.4) 195 (15.0) . 
> 60 955 (10.6) 316 (24.3) . 
Past year quit attempt 522 (54.70) 332 (53.3) 0.545 
Any treatment used 558 (31.5) 194 (30.5) 0.633 
Social Support    
Support of others for quitting  4.4 4.4 0.123 
Social Norms    
Friends/family who smoke    
Almost all 337 (19.1) 151 (23.9) 0.001 
Over half 347 (19.8) 166 (26.3) . 
About half 470 (26.8) 148 (23.4) . 
Less than half 285 (16.2) 82 (12.9) . 
Very few 38 (2.2) 76 (1.4) . 
Home smoking rules    
Smoking is not allowed 891 (50.7) 315 (49.8 0.904 
Smoking is allowed at times 460 (26.2) 167 (26.4) . 
Smoking is allowed 406 (23.1) 151 (23.9) . 
Self-Efficacy    
Quitting self-efficacy 5.09 4.96 0.824 
Readiness to Quit    
Contemplation Ladder 6.39 6.02 0.368 
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reported similarly high rates of past year quit attempts, smokers with SMI were much 
more likely to have used a cessation treatment during the past year. 
In general, smokers with SMI had social environments that were more conducive to 
smoking. Smokers with SMI had greater proportions of family/friends that were current 
smokers, had less restrictive home smoking rules, but had similar levels of social support 
for quitting compared to smokers without SMI. 
Although smokers with SMI had significantly lower self-efficacy for quitting, they did 
not differ from non-SMI smokers in terms of readiness to quit.  
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Table 9. Baseline Demographic, Smoking History, Social Environment, Healthcare 
Provider, and Cessation Belief Characteristics of SMI vs Non-SMI Smokers 
 
Characteristic 
SMI 
N=1044 
Non-SMI 
N=1277 
 
p Value 
 No. (%) or Mean±SD  
Demographics    
Insurance Program    
    Medicaid 861 (82.5) 813 (63.7) <0.001 
    MnCare 183 (17.5) 464 (36.3) . 
Age    
18-24 172 (16.5) 279 (21.9) <0.001 
25-34 344 (33.0) 459 (35.9) . 
35-64 528 (50.6) 539 (42.2) . 
Male 274 (26.3) 412 (32.3) 0.002 
Race/Ethnicity    
White 801 (76.7) 1012 (79.3) 0.078 
Black or African American 130 (12.5) 122 (9.6) . 
Amer Indian or Alaskan Native 79 (7.6) 84 (6.6) . 
Hispanic or Latino 15 (1.4) 27 (2.1) . 
Asian or Pacific Islander 19 (1.8) 32 (2.5) . 
Education    
Grade 11/lower                                                                                                                                                                                                                                                                        161 (15.8) 157 (12.6) 0.001
HS grad/GED 344 (33.8) 418 (33.4) . 
Some college 428 (42.0) 513 (41.0) . 
College grad/higher 85 (8.4) 163 (13.0) . 
Employment     
Employed/self-employed 352 (34.4) 789 (63.0) <0.001 
Student 86 (8.4) 72 (5.8) . 
Out of work 161 (15.7) 138 (11.0) . 
Unable to work/disabled 370 (67.6) 177 (14.1) . 
Homemaker 54 (5.3) 77 (6.2) . 
Yearly income    
Less than $10k 488 (48.8) 350 (28.8) <0.001 
$10,001-$20k 295 (29.5) 403 (33.2) . 
$20,001-$40k 157 (15.7) 312 (25.7) . 
More than $40k 61 (6.1) 150 (12.4) . 
Smoking History    
Cigs/day 14.7±9.6 13.0±8.8 <0.0011 
Duration (yrs) 21.7±12.9 19.7±13.0 <0.001 
Time until 1st cig (mins)    
≤ 5 321 (31.1) 285 (22.6) <0.001 
6 – 15 332 (32.1) 348 (27.6) . 
16 – 30 157 (15.2) 185 (14.7) . 
31 – 60 100 (9.7) 169 (13.4) . 
> 60 123 (11.9) 274 (21.7) . 
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1Satterthwaite test 
 
Main Effect of Intervention 
As described in our prior work,78 participants in the proactive outreach condition had 
higher odds of medication, counselling, and any form of treatment utilization than 
participants in UC (all p<0.001). In addition, participants in the proactive outreach 
condition had higher odds of prolonged abstinence than participants in UC (p=0.006) (see 
Table 10). 
 
Past year quit attempt 565 (55.1) 677 (53.8) 0.536 
Any treatment used 411 (39.4) 328 (25.7) <0.001 
Social Support    
Support of others for quitting  4.4±0.8 4.4±0.7 0.1021 
Social Norms    
Friends/family who smoke    
Almost all 258 (24.9) 221 (17.4) <0.001 
Over half 230 (22.2) 267 (21.1) . 
About half 235 (22.7) 363 (28.7) . 
Less than half 139 (13.4) 199 (15.7) . 
Very few 151 (14.6) 193 (15.2) . 
None 23 (2.2) 24 (1.9)  
Home Environment     
Home smoking rules    
Smoking is not allowed 471 (45.4) 681 (53.8) <0.001 
Smoking is allowed at times 276 (26.6) 333 (26.3) . 
Smoking is allowed 291 (28.0) 253 (20.0) . 
Healthcare Provider    
Regular physician 857 (83.6) 900 (71.6) <0.001 
Physician advised to quit 748 (79.0) 811 (74.5) 0.017 
Physician discussed medications 428 (45.5) 438 (40.4) 0.022 
Physician discussed other  494 (52.5) 466 (42.9) <0.001 
Physician bias 5.9±2.9 5.8±2.8 0.475 
Cessation Beliefs    
Quitting self-efficacy 4.7±3.0 5.3±3.1 <0.001 
Contemplation Ladder 6.3±2.9 6.3±2.9 0.495 
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Table 10. Effect of Proactive Outreach on Cessation Treatment Utilization and 
Prolonged Abstinence  
* Adjusted for stratification variables of sex, age, and insurance program 
 
Cessation Treatment Utilization and Prolonged Abstinence in SMI Group 
In analyses of observed data, SMI participants in the proactive outreach condition had 
higher odds of any form of cessation treatment utilization than participants in UC (51.6% 
vs. 38.1%, OR=1.76, 95% CI: 1.31-2.37, p<0.001). Similar effects were obtained when 
adjusting for variables associated with survey non-response (see Table 11). 
SMI participants in the proactive outreach condition also had higher odds of prolonged 
abstinence than participants in UC, although this effect did not reach significance (14.7% 
vs. 10.8%, OR=1.50, 95% CI: 0.97-2.31, p=0.070). Similar effects were obtained in 
models adjusting for variables associated with survey non-response (see Table 11). 
In analyses of imputed data, the effect of proactive outreach on prolonged abstinence was 
attenuated in both minimally adjusted and fully adjusted models. The effect of proactive 
outreach was strengthened in the analyses of the treatment utilization outcomes and all 
effects remained statistically significant (see Table 11). 
Outcome Usual Care Outreach 
Odds Ratio 
(95% CI) 
 
 p Value 
 (No.) %   
Treatment     
Medication use     
Observed* (278/944) 29.5 (335/826) 40.6 1.63 (1.34-2.00) <0.001 
Counseling use     
Observed* (45/944) 4.8 (174/826) 21.1 5.42 (3.83-7.66) <0.001 
Any trt use     
Observed* (289/944) 30.6 (365/826) 44.2 1.81 (1.48-2.21) <0.001 
Abstinence     
6m prolonged abs     
Observed* (113/937) 12.1 (135/820) 16.5 1.47 (1.12-1.93) 0.006 
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Table 11. Cessation Treatment Utilization and Prolonged Abstinence in SMI Group 
* Adjusted for stratification variables of sex, age, and insurance program 
† Adjusted for stratification variables, race/ethnicity, education, employment, income, 
time until 1st cigarette, and duration of smoking 
 
Cessation Treatment Utilization and Prolonged Abstinence in non-SMI Group 
In analyses of observed data, non-SMI participants in the proactive outreach condition 
had higher odds of any form of cessation treatment utilization than participants in UC 
(38.6% vs. 25.8%, OR=1.79, 95% CI: 1.35-2.37, p<0.001). Similar effects were obtained 
in models adjusting for variables associated with follow-up survey non-response (see 
Table 12). 
Outcome Usual Care Outreach 
Odds Ratio 
(95% CI) 
 
p Value 
Treatment     
Medication use     
Observed* (143/391) 36.6 (176/370) 47.6 1.58 (1.18-2.12) 0.002 
Observed† 36.8 47.3 1.67 (1.22-2.30) 0.002 
Imputed* - - 1.78 (1.34-2.37) <0.001 
Imputed† - - 1.90 (1.41-2.55) <0.001 
Counseling use     
Observed* (25/391) 6.4 (84/370) 22.7 4.43 (2.75-7.15) <0.001 
Observed† 6.3 21.6 4.63 (2.77-7.75) <0.001 
Imputed* - - 6.12 (3.78-9.91) <0.001 
Imputed† - - 6.58(4.01-10.80 <0.001 
Any trt use     
Observed* (149/391) 38.1 (191/370) 51.6 1.76 (1.31-2.37) <0.001 
Observed† 38.3 51.6 1.89 (1.37-2.60) <0.001 
Imputed* - - 2.06 (1.55-2.74) <0.001 
Imputed† - - 2.22 (1.65-3.00) <0.001 
Abstinence     
6m prolonged abs     
Observed* (42/389) 10.8 (54/367) 14.7 1.50 (0.97-2.31) 0.070 
Observed† 9.9 14.5 1.48 (0.90-2.46) 0.126 
Imputed* - - 1.35 (0.90-2.05) 0.115 
Imputed† - - 1.22 (0.79-1.90) 0.370 
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Non-SMI participants in the proactive outreach condition had higher odds of prolonged 
abstinence than participants in UC (18.1% vs. 12.8%, OR=1.55, 95% CI: 1.08-2.23, 
p=0.017). Similar effects were obtained in models adjusting for variables associated with 
follow-up survey non-response (see Table 12). 
In analyses of imputed data, the effect of proactive outreach on prolonged abstinence was 
slightly attenuated, but remained statistically significant across minimally and fully 
adjusted models. The effect of proactive outreach was strengthened in the analyses of the 
treatment utilization outcomes and all effects remained statistically significant (see Table 
12). 
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Table 12. Cessation Treatment Utilization and Prolonged Abstinence in Non-SMI 
Group 
* Adjusted for stratification variables of sex, age, and insurance program 
† Adjusted for stratification variables, race/ethnicity, education, employment, income, 
time until 1st cigarette, and duration of smoking 
 
Tests of Interaction 
The SMI x intervention condition interaction terms in the regressions modeling 
medication use, counseling use, any treatment use, and 6-month prolonged abstinence at 
12-month follow-up were not significant in the analyses of observed data and imputed 
data. 
 
Outcome Usual Care Outreach 
Odds Ratio 
(95% CI) 
 
p Value 
Treatment     
Medication use     
Observed* (130/519) 25.1 (152/428) 35.5 1.63 (1.22-2.17) <0.001 
Observed† 24.8 35.2 1.67 (1.23-2.27) 0.001 
Imputed* - - 1.98 (1.47-2.66) <0.001 
Imputed† - - 2.02 (1.50-2.74) <0.001 
Counseling use     
Observed* (19/519) 3.7 (86/428) 20.1 6.81(4.04-11.48 <0.001 
Observed† 3.5 20.5 7.54(4.33-13.11 <0.001 
Imputed* - - 8.92(5.48-14.52 <0.001 
Imputed† - - 9.13(5.56-14.99 <0.001 
Any trt use     
Observed* (134/519) 25.8 (165/428) 38.6 1.79 (1.35-2.37) <0.001 
Observed† 25.5 38.6 1.86 (1.38-2.51) <0.001 
Imputed* - - 2.42 (1.82-3.22) <0.001 
Imputed† - - 2.49 (1.86-3.33) <0.001 
Abstinence     
6m prolonged abs     
Observed* (66/514) 12.8 (77/425) 18.1 1.55 (1.08-2.23) 0.017 
Observed† 11.9 17.3 1.61 (1.08-2.41) 0.020 
Imputed* - - 1.52 (1.08-2.16) 0.018 
Imputed† - - 1.52 (1.07-2.18) 0.021 
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Discussion 
In concordance with our hypothesis, the proactive outreach intervention was effective for 
promoting all forms of cessation treatment utilization (medication, counseling, and any 
form) for smokers with SMI and those without SMI. In addition, there was a significant 
effect of the intervention on prolonged abstinence in the non-SMI group. Although the 
magnitude of the intervention effect was similar in the SMI group, it did not reach 
statistical significance. Taken in conjunction with the significant main effects of the 
intervention, these results suggest that the proactive outreach strategy was largely 
effective for helping smokers in our low-income sample, regardless of SMI status, 
overcome healthcare provider and psychosocial barriers to treatment utilization and 
abstinence.    
The existing literature suggests that smokers with SMI tend to have more problems 
accessing healthcare, heightened perceptions of physician bias, permissive social 
attitudes toward smoking, and low self-efficacy for quitting. Our baseline analyses 
replicated several of these findings, demonstrating that the SMI smokers in our sample 
lived in social environments that were more conducive to smoking and had lower self-
efficacy for quitting than their non-SMI counterparts. As the OPTIN intervention was 
designed to minimize these barriers through proactive outreach, facilitated access to 
cessation medication, and motivational interviewing, we hypothesized that the 
intervention would be significantly more effective for smokers with SMI. However, it 
was instead found that the effects of the intervention were very similar for smokers with 
and without SMI. 
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The lack of any significant interactions between the intervention and SMI status may be 
better explained in the context of the healthcare characteristics of our study sample. All 
participants in the OPTIN study were enrolled in the publicly-subsidized MHCP which 
provided them with access to free or reduced cost healthcare. This facilitated access to 
care seems to have been of particular benefit for the SMI smokers in our sample, as 
baseline analyses indicated that these smokers were more likely to report having a regular 
physician, had much more frequent interactions with their healthcare providers, and were 
more likely to receive physician-delivered cessation advice than non-SMI smokers. In 
contrast, a significant proportion of the broader population of those with MH disorders do 
not have health insurance, and those with MH disorders tend to be uninsured at higher 
rates than the general population.79 These differing rates of coverage may contribute to 
the disparity in healthcare service utilization observed in previous studies. Thus, the 
increased quality of healthcare experienced by SMI smokers in our sample compared to 
those in the general population may have resulted in a smaller intervention “boost” 
relative to that which was initially hypothesized.  
In addition to reporting frequent quit attempts, smokers with SMI also had much higher 
rates of cessation treatment utilization than non-SMI smokers at baseline. Again, these 
results may in part be explained by the nature of the MHCP healthcare system, which 
appears to provide a comparatively supportive environment for smokers with SMI with 
respect to access and utilization of cessation resources. Despite these high underlying 
rates of treatment use for smokers with SMI, the proactive outreach intervention 
produced similarly sized treatment utilization effects in both groups, and resulted in a 
past year treatment utilization rate of greater than 50% in the SMI group. This suggests 
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that proactive outreach strategies are an effective means of providing a boost in treatment 
utilization rates among smokers who are already in frequent contact with the healthcare 
system and who receive high levels of physician-delivered cessation advice. This result is 
particularly important for smokers with SMI, given evidence which indicates that this 
population may require a greater number of quit attempts and may need to utilize a 
greater number of treatment strategies before achieving cessation.68 
It should be noted that, while the intervention resulted in heightened rates of medication 
use across both groups, it had an even larger effect on the use of counseling. Past year use 
of counseling at baseline was very low in both groups, a finding which is problematic 
given the considerable body of evidence which demonstrates the effectiveness of 
motivational interviewing techniques for boosting quit rates among smokers with and 
without MH disorders. The low underlying rates of counseling use, in combination with 
the high uptake seen in the intervention group, suggests that there may be an unmet 
demand for counseling resources among socioeconomically disadvantaged smokers 
enrolled in publicly-subsidized insurance programs. This result is also an indication that 
cessation counseling that is delivered in a proactive fashion via telephone outreach can 
effectively reduce access barriers. 
Although smokers in the SMI group reported comparatively high rates of treatment 
utilization at follow-up, they achieved lower rates of prolonged abstinence than the non-
SMI group. This finding is consistent with evidence which shows that smokers with MH 
disorders have difficulty quitting80,81 despite engaging in frequent quit attempts, and as 
the present study demonstrates, utilizing cessation treatment at high rates. The 
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intervention produced a moderately sized effect on prolonged abstinence in the SMI 
group, one that was only slightly smaller than that observed in the non-SMI group. This 
finding, although exploratory and not statistically significant, provides preliminary 
evidence that proactive outreach cessation strategies may be effective for smokers with 
SMI. Again, although smokers in our sample accessed cessation treatment at high levels 
at baseline, these results suggest that proactive outreach strategies can provide a 
significant boost in treatment utilization and in abstinence rates.  
Limitations 
Although it is plausible that the proactive outreach intervention would be more effective 
for smokers with SMI given the significant healthcare provider and psychosocial barriers 
experienced by this group, we were unpowered for a formal statistical test of interaction 
by SMI diagnosis. Our study also experienced considerable loss to follow-up, which we 
attempted to account for using imputation methods. In addition, we do not have measures 
of functional impairment to help validate the SMI categorizations. When paired with the 
MH diagnoses, these assessments would help ensure that the smokers in the SMI 
category were experiencing a high degree of life impairment. 
Conclusion 
The present study adds to the body of evidence demonstrating that smokers with SMI are 
interested in quitting and take up treatment at high rates when it is offered.26–28 
Examination of baseline rates of physician-delivered cessation advice and treatment 
utilization among SMI smokers in this sample also shows that MHCP is providing a 
relatively supportive cessation environment for smokers with SMI, particularly in light of 
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past evidence demonstrating the disparity in cessation-related care experienced by these 
smokers in the broader US population. Our results suggest that proactive outreach 
strategies are effective for boosting rates of treatment utilization among smokers with 
SMI, even among those already receiving high rates of quality cessation care from their 
healthcare providers. These interventions may be particularly useful for boosting rates of 
counseling use, which were discouragingly low at baseline. Furthermore, this study 
provides evidence that proactive outreach may be effective for boosting abstinence rates 
among smokers with SMI, although further research is needed to replicate these findings. 
It is critically important that public health experts continue to develop and evaluate 
strategies for increasing rates of smoking cessation and reducing the disparity in 
smoking-related morbidity and mortality experienced by those with MH disorders.   
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Research Study 3 
Title: The effect of prolonged smoking cessation on binge drinking and mental health 
among smokers with serious mental illness 
Specific Aims 
Aim 1: To examine the effect of 6-month prolonged smoking cessation on binge drinking 
among smokers with SMI and smokers without SMI.  
Hypothesis 1: Smoking cessation will be associated with a reduction in binge 
drinking among smokers with SMI and smokers without SMI.  
Aim 2: To examine the effect of 6-month prolonged smoking cessation on depression and 
anxiety symptoms among smokers with SMI and smokers without SMI.  
Hypothesis 2: Smoking cessation will be associated with improvement in 
depression and anxiety symptoms among smokers with SMI and smokers without 
SMI.  
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Abstract 
Introduction 
The overall prevalence of smoking is declining, but rates of smoking remain high for 
those with alcoholism and SMI. The challenges inherent in quitting smoking may seem 
particularly daunting for these smokers given the common perceptions that quitting 
smoking will exacerbate MH symptoms and lead to increases in alcohol abuse behaviors. 
The aims of the present study are to address these longstanding perceptions by exploring 
the effect of incident smoking cessation on binge drinking and symptoms of depression 
and anxiety.   
Methods 
We present data from secondary analyses of the OPTIN study. ICD-9 codes obtained 
from insurance claims data were used to identify participants with schizophrenic 
disorders, psychotic disorder, bipolar disorders, and/or major depressive disorder. These 
diagnoses were used to categorize participants into SMI (n=1044) and non-SMI (n=1277) 
groups. Multivariable linear regressions modeled the effects of 6-month prolonged 
cessation (yes vs.no) on PHQ-2 depression scores, PROMIS anxiety scores, and binge 
drinking at 12-month follow-up in the SMI and non-SMI groups, respectively.   
Results 
In the minimally adjusted models, smokers who quit had far lower odds of binge drinking 
more than 3 days per month than those who did not quit in both the SMI (OR=0.26, 95% 
CI: 0.09-0.76) and the non-SMI group (OR=0.42, 95% CI: 0.21-0.87), although the 
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overall effects of quitting smoking did not reach statistical significance. Smokers who 
quit also had lower PHQ-2 scores in both the SMI (2.37 vs 2.71, p=0.042) and the non-
SMI group (1.59 vs 1.75, p=0.065). Smokers who quit reported lower PROMIS anxiety 
scores in the SMI group (55.61 vs. 59.03, p<0.001), but this effect did not reach 
significance in the non-SMI group. 
Conclusion 
Smoking cessation was associated with reductions in binge drinking as well as symptoms 
of depression and anxiety in both the SMI and non-SMI groups. These findings counter 
the narrative that quitting smoking is detrimental for those with MH disorders and bolster 
the case for promoting cessation among these smokers and helping facilitate access to 
cessation resources. 
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Introduction 
The prevalence of smoking among those with MH disorders is two to three times higher 
than that of the general US population, depending on clinical diagnosis.8 Those with 
diagnoses consistent with SMI like major depressive disorder82,83 and schizophrenia84 are 
also more likely to engage in alcohol abuse behaviors. Furthermore, evidence suggests 
that smoking and alcoholism tend to co-occur as the prevalence of alcohol dependence 
among current smokers is nearly 10 times that of non-smokers.85 The high co-occurrence 
of smoking and alcohol dependence among those with SMI is a grave public health 
concern. In addition to the well-established cardiovascular and hepatic risks associated 
with these behaviors,86,87 the combined use of cigarettes and alcohol is associated with a 
multiplicative increase in the risk for certain head and neck cancers.88  
Many smokers with alcohol use disorder report using smoking as a way to cope with 
urges to drink,54 making the prospect of quitting seem overwhelming and unattainable. 
Furthermore, the strong withdrawal symptoms associated with smoking cessation and 
abstinence from alcohol have contributed to a reluctance to treat these conditions 
simultaneously,55,56 largely due to the belief that achieving abstinence in one of these 
behaviors will lead to exacerbation of the other.57 Smokers with alcohol use disorder 
often echo these concerns with many of them espousing the belief that quitting smoking 
would harm their sobriety.54 Some early research partially validates these concerns, as 
several studies have demonstrated that smoking cessation is associated with increased 
alcohol use.89,90 However, more recent studies have shown that alcohol use does not 
substantially change following smoking cessation91,92 or is actually reduced.57,93 It has 
	 75 
been suggested that methodological variability, recall bias, and an inability to establish 
temporal ordering may account for the inconsistent findings across these studies.57  
A key barrier to smoking cessation among those with SMI is the perception that engaging 
in a quit attempt may exacerbate their MH symptoms. This perception exists at both the 
individual level and at the level of the healthcare provider. Evidence suggests that 
smokers with SMI may use nicotine as a form of self-medication to help reduce the 
experience of negative affect and anxiety associated with their condition(s),47,48 and 
qualitative work has shown that these smokers expect that their MH will deteriorate 
following a quit attempt.35 Healthcare providers similarly endorse the belief that quitting 
may heighten the depressive symptoms of their patients.37,38  
Despite the concerns of both smokers and healthcare providers regarding the potentially 
deleterious consequences associated with smoking cessation, a growing body of evidence 
suggests that quitting smoking leads to improved MH among the general population.94–96 
Other research has shown similarly beneficial effects of smoking cessation on MH 
symptoms among smokers with diagnoses of mood and anxiety disorders.97  
The inconsistent findings regarding the effects of smoking cessation on alcohol use 
highlight the need for continued research exploring this issue. As such, the first aim of 
the present study is to assess the effect of smoking cessation on behaviors consistent with 
alcohol abuse. We will specifically focus on binge drinking behaviors given the 
pronounced deleterious health risks associated with drinking to excess98–100 and because 
binge drinking is a predictor of alcohol dependence.101 There is also a lack of research 
exploring whether the effects of smoking cessation on alcohol use differ by SMI status; 
	 76 
an important clinical consideration when approaching the treatment of smoking for those 
with MH disorders due to the high co-morbidity of these conditions.82,102 We will address 
this gap in the literature by examining the effect of smoking cessation on binge drinking 
among those with SMI and without SMI, respectively.  
The second aim of this study is to explore the effects of smoking cessation on MH 
symptoms. Continued research in this area is essential in order to better inform both 
smokers and physicians on what to expect when approaching cessation, an issue of 
particular importance for smokers with SMI. On the part of the smoker, this information 
may allay fears regarding MH symptom exacerbation and boost motivation to quit and 
enhance self-efficacy. For healthcare providers, this information may be useful when 
providing clinical care for cessation and when considering treatment options. Developing 
individually-tailored treatment plans may be particularly useful if the effects of smoking 
cessation on MH differs for smokers with and without SMI. In light of evidence which 
suggests that tobacco use can reduce the effectiveness of common antipsychotic and 
antidperessant medications,53 it is also plausabile that prolonged cessation may be 
particularly beneficial for smokers with SMI. As such, we will examine the effects of 
prolonged smoking cessation on MH symptoms among smokers with and without SMI. 
Methods 
Study Design 
Data were obtained from the OPTIN study (N=2406). This study was a two-arm RCT 
that demonstrated the effectiveness of proactive outreach on 6-month prolonged 
abstinence in a sample of smokers enrolled in MHCP.70 The study population sample was 
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stratified by age group (18–24, 25–34, 35–64), gender (male or female), and insurance 
program (Medicaid or MinnesotaCare). Using MHCP insurance claims drawn from a 2-
year period prior to study initiation, ICD-9 codes indicative of schizophrenic disorders, 
psychotic disorder, bipolar I and II disorder, and/or major depressive disorder were used 
to categorize participants as having SMI (n=1044) or not having SMI (n=1277). 
Measures 
Measures were obtained from OPTIN baseline and follow-up survey data, as well as from 
MHCP administrative and claims data. 
Demographics 
Age, sex, insurance program, education, employment status, income, and race/ethnicity 
were assessed. The “Hispanic” and “Asian/Pacific Islander” categories were collapsed 
into one category due to the small sizes of these groups. 
Smoking History 
Standard questions from the California Tobacco Survey62 and the BRFSS63 assessed 
smoking history, including lifetime duration of smoking, time until first cigarette, 
cigarettes smoked per day, and past year quit attempts. 
Smoking Abstinence  
A self-report measure was used to assess 6-month prolonged abstinence at 12-month 
follow-up.71 Participants who reported smoking at least once on 7 consecutive days or at 
least once on 2 consecutive weekends in the 6-month period prior to the follow-up survey 
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were considered continuing smokers. 
Social Environment 
A composite variable measured participants’ perceived social support for cessation by 
taking the mean of two support-related variables that assessed perceived support for 
quitting and others’ desire for quitting, respectively.28 All items were assessed on a 5-
point scale, with higher scores indicative of greater levels of social support. Participants 
reported the proportion of their close friends and family who were smokers. Participants 
then reported whether they lived with a child under the age of 18, whether they lived with 
another smoker, and the smoking rules within their home. 
Healthcare Provider Factors 
HEDIS tobacco performance measures were used to assess participants’ past year 
healthcare experiences.26 Items assessed whether participants received physician-
delivered advice to quit, advice to use cessation medications, and advice to use ways 
(besides products) to help with quitting. A composite variable of perceptions of 
healthcare provider bias was created by summing 3 items from the Physician Bias and 
Interpersonal Cultural Competence Measures Scale.27 Each item was assessed on a 5-
point scale, with higher values indicating greater perceptions of physician bias.  
Mental Health Diagnoses 
Participants with at least one ICD-9 code in the range of 1) 295.00 to 295.94 were 
considered to have a schizophrenic disorder, 2) 297.00 to 298.9 were considered to have 
a psychotic disorder, 3) 296.2 to 296.36 were considered to have a major depressive 
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disorder, 4) 296.00 to 296.13 and/or 296.4 to 296.9 were considered to have a bipolar 
disorder. 
Mental Health Symptoms 
Measures taken from the PROMIS instrument were used to assess mental health 
symptoms.103 The anxiety measure was created by taking the sum of 7 items assessed on 
a scale from 1-5, with higher scores indicating greater anxiety. A T-score was then 
calculated by multiplying the summed score by 7 and dividing by the number of items 
that the participant answered (see Appendix). The depression measure was created by 
taking the sum of 2 items assessed on a scale from 1-4, with higher scores indicating 
greater depressive thoughts (see Appendix).  
Alcohol  
An item from the BRFSS was used to assess binge drinking by asking on how many days 
in the past 30 the participant had consumed 5 or more drinks (4 or more for women). 
Participants were placed into “0 days”, “1 day”, “2-3 days”, or “more than 3 days” 
categories (see Appendix). 
Statistical Analysis 
Bivariate Analyses 
Bivariate analyses, performed using t-tests and Person’s chi-square, were used to 
compare participants with and without SMI across demographic, smoking history, 
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cessation treatment utilization, healthcare provider, social environment, and psychosocial 
measures. 
Regression Analyses 
Multivariable multinomial regression was used to model the effect of 6-month prolonged 
smoking cessation (yes vs. no) on the 4-level binge drinking outcome variable at 12-
month follow-up, stratified by SMI category (SMI vs. non-SMI). A baseline measure of 
binge drinking was included in these models.  
Log transformations of the depression and anxiety outcome variables and their respective 
baseline measures were performed to address right skewing. All means reported in these 
outcomes analyses are geometric means that have been exponentiated from the log form. 
Multivariable linear regressions were used to model the effect of prolonged cessation on 
PHQ-2 depression score and PROMIS anxiety score at follow-up, stratified by SMI 
category. Baseline measures of each outcome variable were included in their respective 
models.   
Post-Hoc Multinomial Regression Analyses 
In order to account for the low statistical power of the binge drinking outcome, and due 
to the similarity of effects observed across the SMI and non-SMI groups, a post-hoc 
analysis was conducted to examine the main effect of smoking cessation on binge 
drinking in the combined SMI and non-SMI sample. 
Confounder Adjustment 
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A series of bivariate analyses were conducted comparing those who quit smoking vs. 
continuing smokers across a series of potential demographic, smoking history, social 
environment, and smoking beliefs confounders (see Table 13). The analyses indicate that 
quitters tended to score lower on indicators of nicotine dependence, but were less likely 
to have engaged in a quit attempt at baseline. In addition, quitters were less likely to 
report having received advice to quit or to use cessation medication from their healthcare 
provider. Quitters also reported social environments that were less conducive to smoking, 
particularly with respect to home smoking rules. Quitters reported much higher self-
efficacy for quitting and readiness to quit at baseline.  
In addition to the unadjusted regression models, hierarchical models were used to 
incrementally adjust for the effects of the 1) intervention 2) demographic 3) social 
environment, and 4) smoking history/cessation beliefs variables.  
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Table 13. Intervention, Demographic, Social Environment, and Smoking 
History/Cessation Beliefs Characteristics of Smoking Quitters Vs. Non-Quitters  
 
Characteristic 
Smoking 
Quitter 
N=248 
Smoking     
Non-Quitter 
N=1509 
 
 
p Value 
 No. (%) or Mean  
Intervention     
Proactive outreach 135 (54.4) 685 (45.4) 0.008 
Usual care 113 (45.6) 824 (54.6) . 
Demographics    
Age    
18-24 51 (20.6) 263 (17.4) 0.323 
25-34 84 (33.9) 488 (32.3) . 
35-64 113 (45.6) 758 (50.2) . 
Male 77 (31.1) 430 (28.5) 0.411 
Race/Ethnicity    
White 186 (75.0) 1206 (79.9) 0.112 
Black or African 
American 30 (12.1) 158 (10.5) . 
Amer Ind or Alaskan 
Native 17 (6.9) 101 (6.7) . 
Hispanic or Latino 7 (2.8) 22 (1.5) . 
Asian or Pacific Islander 8 (3.2) 22 (1.5) . 
Education    
Grade 11/lower                                                                                                                                                                                                                                                                        32 (13.2) 163 (11.0) 0.504 
HS grad/GED 72 (29.6) 486 (32.9) . 
Some college 204 (42.8) 647 (43.8) . 
College grad/higher 35 (14.4) 181 (12.3) . 
Employment     
Employed/self-employed 128 (52.9) 746 (50.2) 0.189 
Student 15 (6.2) 102 (6.9) . 
Out of work 18 (7.4) 189 (12.7) . 
Unable to work/disabled 67 (27.7) 362 (24.5) . 
Homemaker 14 (5.8) 86 (5.8) . 
Yearly income    
Less than $10k 76 (32.5) 531 (36.7) 0.117 
$10,001-$20k 93 (39.7) 459 (31.7) . 
$20,001-$40k 44 (18.8) 306 (21.2) . 
More than $40k 21 (8.9) 151 (10.4) . 
Social Norms    
Friends/family who smoke    
Almost all 38 (15.5) 297 (19.8) <0.001 
Over half 34 (13.9) 308 (20.6) . 
About half 65 (26.5) 403 (26.9) . 
Less than half 39 (15.9) 242 (16.2) . 
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1Satterthwaite test 
2Geometric means are reported 
 
Results 
Baseline Comparison of Smokers with SMI vs without SMI  
Compared to non-SMI smokers (n=1277), those with SMI (n=1044) were more likely to 
be enrolled in Medicaid, were older, and more likely to be female. Smokers with SMI 
also tended to be less educated, less likely to be currently employed, and earned 
significantly less (see Table 14). 
With respect to mental health and alcohol use characteristics, smokers with SMI had 
significantly more symptoms of depression and anxiety at baseline, were more likely to 
have a diagnosis of alcohol dependence disorder, but had lower levels of binge drinking 
(see Table 14). 
Very few 58 (23.7) 221 (14.8) . 
None 11 (4.5) 27 (1.8)  
Home smoking rules    
Smoking is not allowed 155 (63.5) 730 (48.7) <0.001 
Smoking is allowed at 
times 54 (22.1) 402 (26.8) . 
Smoking is allowed 35 (14.3) 368 (24.5) . 
Smoking History    
Cigs/day 9.8±10.8 14.2±8.8 <0.0011 
Duration (yrs) 19.7±13.8 21.7±13.2 0.034 
Time until 1st cig (mins)    
≤ 5 33 (14.0) 401 (26.7) <0.001 
6 – 15 50 (21.3) 450 (30.0) . 
16 – 30 27 (11.5) 240 (16.0) . 
31 – 60 35 (14.9) 174 (11.6) . 
> 60 90 (38.3) 235 (15.7) . 
Cessation Beliefs    
Quitting self-efficacy 7.0±2.9 4.8±3.0 <0.001 
Contemplation Ladder 7.4±2.9 6.2±2.8 <0.001 
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Smokers with SMI had more indicators of nicotine dependence, including less time until 
smoking their first cigarette after waking. They also tended to be heavier smokers and 
had smoked for a longer duration of time than those without SMI. Smokers with SMI had 
lower quitting self-efficacy but reported similar readiness to quit as those without SMI. 
Smokers in the SMI group also had more smokers in their peer groups and had less 
restrictive home smoking rules (see Table 14). 
Smokers with SMI were more likely to report having a regular doctor, and received more 
advice to quit and to use cessation treatments than non-SMI smokers (see Table 14). 
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Table 14. Baseline Demographic, Mental Health/Alcohol, Smoking History, Social 
Environment, Healthcare Provider, and Cessation Belief Characteristics of SMI vs. Non-
SMI Smokers 	
 
Characteristic 
SMI 
N=1044 
Non-SMI 
N=1277 
 
p Value 
 No. (%) or Mean±SD  
Demographics    
Insurance Program    
    Medicaid 861 (82.5) 813 (63.7) <0.001 
    MnCare 183 (17.5) 464 (36.3) . 
Age    
18-24 172 (16.5) 279 (21.9) <0.001 
25-34 344 (33.0) 459 (35.9) . 
35-64 528 (50.6) 539 (42.2) . 
Male 274 (26.3) 412 (32.3) 0.002 
Race/Ethnicity    
White 801 (76.7) 1012 (79.3) 0.078 
Black or African American 130 (12.5) 122 (9.6) . 
Amer Indian or Alaskan Native 79 (7.6) 84 (6.6) . 
Hispanic or Latino 15 (1.4) 27 (2.1) . 
Asian or Pacific Islander 19 (1.8) 32 (2.5) . 
Education    
Grade 11/lower                                                                                                                                                                                                                                                                        161 (15.8) 157 (12.6) 0.001 
HS grad/GED 344 (33.8) 418 (33.4) . 
Some college 428 (42.0) 513 (41.0) . 
College grad/higher 85 (8.4) 163 (13.0) . 
Employment     
Employed/self-employed 352 (34.4) 789 (63.0) <0.001 
Student 86 (8.4) 72 (5.8) . 
Out of work 161 (15.7) 138 (11.0) . 
Unable to work/disabled 370 (67.6) 177 (14.1) . 
Homemaker 54 (5.3) 77 (6.2) . 
Yearly income    
Less than $10k 488 (48.8) 350 (28.8) <0.001 
$10,001-$20k 295 (29.5) 403 (33.2) . 
$20,001-$40k 157 (15.7) 312 (25.7) . 
More than $40k 61 (6.1) 150 (12.4) . 
Mental Health    
Depression2 2.8±1.9 1.9±1.9 <0.001 
Anxiety2 58.6±1.2 51.0±1.2 <0.001 
Alcohol    
Alcohol dependence disorder 355 (34.0) 100 (7.8) <0.001 
Binge drinking (past month)   <0.001 
0 days 641 (65.5) 658 (54.0) . 
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1 day 91 (9.3) 148 (12.1) . 
2-3 days 99 (10.1) 200 (16.4) . 
> 2-3 days 147 (15.0) 213 (17.5) . 
Smoking History    
Cigs/day 14.7±9.6 13.0±8.8 <0.0011 
Duration (yrs) 21.7±12.9 19.7±13.0 <0.001 
Time until 1st cig (mins)    
≤ 5 321 (31.1) 285 (22.6) <0.001 
6 – 15 332 (32.1) 348 (27.6) . 
16 – 30 157 (15.2) 185 (14.7) . 
31 – 60 100 (9.7) 169 (13.4) . 
> 60 123 (11.9) 274 (21.7) . 
Smoking Abstinence    
6-month prolonged 96 (12.7) 143 (15.2) 0.137 
Social Norms    
Friends/family who smoke    
Almost all 258 (24.9) 221 (17.4) <0.001 
Over half 230 (22.2) 267 (21.1) . 
About half 235 (22.7) 363 (28.7) . 
Less than half 139 (13.4) 199 (15.7) . 
Very few 151 (14.6) 193 (15.2) . 
None 23 (2.2) 24 (1.9)  
Home smoking rules    
Smoking is not allowed 471 (45.4) 681 (53.8) <0.001 
Smoking is allowed at times 276 (26.6) 333 (26.3) . 
Smoking is allowed 291 (28.0) 253 (20.0) . 
Healthcare Provider    
Regular physician 857 (83.6) 900 (71.6) <0.001 
Physician advised to quit 748 (79.0) 811 (74.5) 0.017 
Physician discussed medications 428 (45.5) 438 (40.4) 0.022 
Physician discussed other  494 (52.5) 466 (42.9) <0.001 
Physician bias 5.9±2.9 5.8±2.8 0.475 
Cessation Beliefs    
Quitting self-efficacy 4.7±3.0 5.3±3.1 <0.001 
Contemplation Ladder 6.3±2.9 6.3±2.9 0.495 
1Satterthwaite test 
2Geometric means are reported 
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Binge Drinking at Follow-up in Smoking Quitters vs. Non-Quitters 
SMI Group 
In the minimally adjusted model (model 2), smokers who quit had lower odds of binge 
drinking for 2-3 days (OR=0.68, 95% CI: 0.28-1.63) and more than 3 days (OR=0.26, 
95% CI: 0.09-0.76) compared to no days of binge drinking than those who did not quit. 
The overall effect was marginally significant (p<0.1) in model 2, but did not reach 
significance in the more fully adjusted models (see Table 15).  
Non-SMI Group 
In the minimally adjusted model, smokers who quit had lower odds of binge drinking for 
2-3 days (OR=0.58, 95% CI: 0.30-1.13) and more than 3 days (OR=0.42, 95% CI: 0.21-
0.87) compared to no days of binge drinking than those who did not quit (see Table 15). 
The overall effects were marginally significant (p<0.1) in models 2 through 4.
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Table 15. Binge Drinking at Follow-Up in Smoking Quitters vs Non-Quitters by SMI Group 
 
Model 1 is unadjusted 
Model 2 is adjusted for baseline binge drinking and intervention  
Model 3 is adjusted for baseline binge drinking, intervention, and socio-demographics 
Model 4 is adjusted for baseline binge drinking, intervention, socio-demographics, and social environment 
SMI (N=667) 
Model 
Smoking 
Quitter 
Binge 
Drink OR (95% CI) 
p    
Value 
1 Yes vs No 
0 days - - 
1 day 0.89 (0.39-2.05) 0.152 
2-3 day 0.78 (0.36-1.69) - 
> 3 days 0.34 (0.13-0.87) - 
2 Yes vs No 
0 days - - 
1 day 0.99 (0.42-2.34) 0.096 
2-3 day 0.68 (0.28-1.63) - 
> 3 days 0.26 (0.09-0.76) - 
3 Yes vs No 
0 days - - 
1 day 1.11 (0.46-2.71) 0.213 
2-3 day 0.79 (0.32-1.95) - 
> 3 days 0.30 (0.09-0.94) - 
4 Yes vs No 
0 days - - 
1 day 0.98 (0.39-2.45) 0.441 
2-3 day 0.80 (0.32-2.01) - 
> 3 days 0.38 (0.12-1.22) - 
5 Yes vs No 
0 days - - 
1 day 0.88 (0.33-2.39) 0.310 
2-3 day 0.71 (0.27-1.88) - 
> 3 days 0.30 (0.08-1.06) - 
Non-SMI (N=865) 
Model 
Smoking 
Quitter 
Binge 
Drink OR (95% CI) 
p    
Value 
1 Yes vs No 
0 days - - 
1 day 1.08 (0.63-1.87) 0.100 
2-3 day 0.72 (0.41-1.28) - 
> 3 days 0.51 (0.28-0.92) - 
2 Yes vs No 
0 days - - 
1 day 0.91 (0.49-1.70) 0.087 
2-3 day 0.58 (0.30-1.13) - 
> 3 days 0.42 (0.21-0.87) - 
3 Yes vs No 
0 days - - 
1 day 0.92 (0.47-1.78) 0.080 
2-3 day 0.58 (0.29-1.18) - 
> 3 days 0.30 (0.17-0.83) - 
4 Yes vs No 
0 days - - 
1 day 1.04 (0.53-2.06) 0.074 
2-3 day 0.61 (0.29-1.24) - 
> 3 days 0.38 (0.17-0.84) - 
5 Yes vs No 
0 days - - 
1 day 1.13 (0.53-2.38) 0.191 
2-3 day 0.66 (0.30-1.46) - 
> 3 days 0.42 (0.17-1.03) - 
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Model 5 is adjusted for baseline binge drinking, intervention, socio-demographics, social environment, and smoking 
characteristics 	
		 90 
Post-Hoc Binge Drinking at Follow-up in Smoking Quitters vs. Non-Quitters 
Combined SMI and Non-SMI sample  
In the minimally adjusted model (model 2), smokers who quit had lower odds of binge 
drinking for 2-3 days (OR=0.61, 95% CI: 0.36-1.03) and more than 3 days (OR=0.37, 
95% CI: 0.21-0.67) compared to no days of binge drinking than those who did not quit 
(see Table 16). These effects were largely consistent across all levels of adjustment. 
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Table 16. Binge Drinking at Follow-Up in Smoking Quitters vs                                              
Non-Quitters in Combined Sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model 1 is unadjusted 
Model 2 is adjusted for baseline binge drinking and intervention  
Model 3 is adjusted for baseline binge drinking, intervention,  
and socio-demographics 
Model 4 is adjusted for baseline binge drinking, intervention,  
socio-demographics, and social environment 
Model 5 is adjusted for baseline binge drinking, intervention,  
socio-demographics, social environment, and smoking characteristics
All (N=1532) 
Model 
Smoking 
Quitter 
Binge 
Drink OR (95% CI) 
p   
Value 
1 Yes vs No 
0 days - - 
1 day 1.05 (0.67-1.66) 0.014 
2-3 day 0.76 (0.48-1.20) - 
> 3 days 0.46 (0.28-0.75) - 
2 Yes vs No 
0 days - - 
1 day 0.97 (0.59-1.59) 0.006 
2-3 day 0.61 (0.36-1.03) - 
> 3 days 0.37 (0.21-0.67) - 
3 Yes vs No 
0 days - - 
1 day 1.00 (0.60-1.69) 0.011 
2-3 day 0.64 (0.37-1.11) - 
> 3 days 0.36 (0.19-0.67) - 
4 Yes vs No 
0 days - - 
1 day 1.05 (0.62-1.78) 0.019 
2-3 day 0.68 (0.39-1.18) - 
> 3 days 0.37 (0.19-0.72) - 
5 Yes vs No 
0 days - - 
1 day 0.98 (0.55-1.74) 0.034 
2-3 day 0.65 (0.36-1.12) - 
> 3 days 0.36 (0.18-0.73) - 
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PHQ-2 Scores at Follow-up in Smoking Quitters vs. Non-Quitters 
SMI Group 
In the minimally adjusted model (model 2), smokers who quit reported lower depression 
scores than those who did not quit (2.37 vs. 2.71, p = 0.042). This effect was attenuated 
in the most fully adjusted model (see Table 17).  
Non-SMI Group 
In the minimally adjusted model, smokers who quit reported lower depression scores than 
those who did not quit (1.59 vs. 1.75, p = 0.065). This effect was slightly strengthened in 
more fully adjusted models, reaching significance in models two and three (see Table 
17).  
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Table 17. PHQ-2 Depression Scores at Follow-Up in Smoking Quitters vs Non-Quitters by SMI Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model 1 is unadjusted 
Model 2 is adjusted for baseline PHQ-2 score and intervention  
Model 3 is adjusted for baseline PHQ-2 score, intervention, and socio-demographics 
Model 4 is adjusted for baseline PHQ-2 score, intervention, socio-demographics, and social environment 
Model 5 is adjusted for baseline PHQ-2 score, intervention, socio-demographics, social environment, and smoking 
characteristics 
*Least squares geometric mean 	
SMI (N=650) 
Model 
Smoking 
Quitter 
T2 
Mean* 
Mean 
Diff p Value 
1 Yes 2.34 0.38 0.048 No 2.72 - - 
2 Yes 2.37 0.34 0.042 No 2.71 - - 
3 Yes 2.37 0.30 0.087 No 2.67 - - 
4 Yes 2.20 0.31 0.060 No 2.51 - - 
5 Yes 2.52 0.16 0.427 No 2.68 - - 
Non-SMI (N=817) 
Model 
Smoking 
Quitter 
T2 
Mean* 
Mean 
Diff 
p 
Value 
1 Yes 1.41 0.26 0.064 No 1.67 - - 
2 Yes 1.59 0.16 0.065 No 1.75 - - 
3 Yes 1.46 0.16 0.047 No 1.62 - - 
4 Yes 1.48 0.22 0.033 No 1.66 - - 
5 Yes 1.49 0.18 0.071 No 1.67 - - 
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PROMIS Anxiety Scores at Follow-up in Smoking Quitter vs. Non-Quitters 
SMI Group 
In the minimally adjusted model (model 2), smokers who quit reported lower anxiety 
scores than those who did not quit (55.61 vs. 59.03, p <0.001). This effect was attenuated 
in subsequent models but remained significant (see Table 18). 
Non-SMI Group 
In the minimally adjusted model (model 2), smokers who quit reported lower anxiety 
scores than those who did not quit (48.96 vs. 50.21, p <0.001), but this effect was not 
significant (p=0.131). The effect of abstinence on anxiety scores was strengthened in the 
most fully adjusted model (46.47 vs. 48.22, p=0.062) (see Table 18). 
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Table 18. PROMIS Anxiety Scores at Follow-Up in Smoking Quitters vs Non-Quitters by SMI Group 
 
 
 
 
 
 
 
 
 
 
 
 
Model 1 is unadjusted 
Model 2 is adjusted for baseline PROMIS anxiety score and intervention  
Model 3 is adjusted for baseline PROMIS anxiety score, intervention, and socio-demographics 
Model 4 is adjusted for baseline PROMIS anxiety score, intervention, socio-demographics, and social environment 
Model 5 is adjusted for baseline PROMIS anxiety score, intervention, socio-demographics, social environment, and 
smoking characteristics 
*Least squares geometric mean
SMI (N=738) 
Model 
Smoking 
Quitter 
T2 
Mean* 
Mean 
Diff 
p 
Value 
1 Yes 54.62 4.53 <0.001 No 59.15 - - 
2 Yes 55.63 3.40 <0.001 No 59.03 - - 
3 Yes 56.67 2.36 0.004 No 59.61 - - 
4 Yes 55.94 2.78 0.007 No 58.72 - - 
5 Yes 56.41 2.40 0.035 No 58.81 - - 
Non-SMI (N=906) 
Model 
Smoking 
Quitter 
T2 
Mean* 
Mean 
Diff 
p 
Value 
1 Yes 49.23 0.91 0.327 No 50.14 - - 
2 Yes 48.96 1.25 0.131 No 50.21 - - 
3 Yes 47.51 1.34 0.107 No 48.85 - - 
4 Yes 47.18 1.25 0.138 No 48.43 - - 
5 Yes 46.47 1.75 0.062 No 48.22 - - 
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Discussion 
The overall effect of quitting smoking on binge drinking was not significant in either the 
SMI or non-SMI group. However, a trend did exist such that those who quit had lower 
odds of binge drinking for 2-3 days or more than 3 days compared to those who did not 
quit. This trend remained consistent in analyses of the combined SMI and non-SMI 
sample. Regardless of SMI status, smokers who quit reported lower levels of depression 
and anxiety at 12-month follow-up than those who did not quit. The direction of these 
effects remained consistent across all levels of adjustment, although there was some 
attenuation in the SMI group. When examined in parallel, the association between 
smoking cessation and reductions in MH symptoms was slightly stronger among those 
with SMI compared to those without SMI.  
The finding that smoking cessation did not appear to exacerbate binge drinking, and may 
be associated with reductions in this behavior, has important implications for our low-
income sample. Foremost, it contradicts a long-held assumption that the challenges 
inherent in quitting smoking, particularly coping with withdrawal symptoms, may be 
compensated for by increasing other substance use behaviors.55,104 Given the reductions 
in binge drinking noted among those who quit smoking, it appears that any uptick in 
problematic alcohol use following cessation, if present at all, does not persist once an 
individual has been quit for a prolonged period of time. This result can also be viewed as 
promising given evidence showing that smoking can be used as a means of coping with 
the urge to drink among those with alcohol use disorders.54 These beliefs and coping 
strategies can have the effect of reducing the motivation and perceived ability to quit 
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among those with co-morbid alcohol dependence.104 Despite these negative expectations 
about quitting smoking, there was a relatively high rate of cessation in our sample (14.1% 
overall) and on the whole those who quit did not experience an increase in binge 
drinking.  
These results have particular relevance for smokers with SMI. First, while only a subset 
of the smokers in the SMI group had a diagnosis of alcohol dependence disorder (34%), 
this rate was far higher than that seen in the non-SMI group (8%) and in the general US 
population (3.5%).105 As such, the perception that attempting cessation will exacerbate 
alcohol abuse behaviors likely plays a more significant role in discouraging cessation 
among this group of smokers. Despite the high rate of alcohol dependence, cessation was 
not associated with heightened rates of binge drinking. These results suggest that 
cessation should be encouraged among smokers with SMI, and that the benefits of 
providing a counter-narrative to the “quitting smoking is dangerous” argument may carry 
greater weight within this population. In addition, it should be noted that the SMI 
smokers in our sample tended to have lower self-efficacy for quitting than the non-SMI 
smokers, a finding which is consistent with past research.35,51,52 Providing these smokers 
with accurate information regarding the consequences of smoking cessation may help to 
boost self-efficacy for quitting by providing them with a more complete picture of how 
cessation could affect their propensity to drink. 
In assessing our secondary aim, we were able to replicate the finding that cessation is 
associated with improvements in MH for those without SMI, providing further evidence 
for more wide-ranging beneficial effects of cessation aside from the obvious 
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cardiovascular benefits. Our study was also one of the first to demonstrate the beneficial 
effects of cessation on MH symptoms among those with SMI; a finding that runs counter 
to the prevailing narrative that quitting smoking can be detrimental to the MH of this 
group. This information may be useful in helping to dispel the notion that quitting 
smoking is not a treatment priority for smokers with SMI. By demonstrating that the act 
of quitting smoking may in itself provide modest relief of MH symptoms, it is easier to 
prioritize offering these smokers advice to quit and access to cessation resources.  
Although baseline analyses indicate that smokers with SMI were provided with relatively 
high rates of cessation and treatment utilization advice from their healthcare providers, 
the use of individualized feedback to address cessation barriers may help to maximize the 
effectiveness of this advice. The recently validated Barriers to Quitting Smoking in 
Substance Abuse Treatment (BQS-SAT) scale can be used to assess perceived barriers to 
quitting,106 including concerns regarding the potential effects of cessation on MH. 
Physicians can assess these concerns and then provide smokers with more accurate 
information on the quitting process, thereby increasing motivation and self-efficacy for 
quitting. 
Quitting smoking is a daunting prospect for any smoker, but it can be particularly 
challenging for those with a history of alcoholism who are attempting to remain sober. 
The high prevalence of smoking among those involved in alcohol recovery organizations 
like Alcoholics Anonymous (AA) may actually have a detrimental impact on these 
individuals’ motivation to quit. While AA no doubt provides an important support 
network for those living with alcoholism, smoking remains highly prevalent among those 
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attending AA meetings107 and may be used as a means of coping with the urge to drink. 
By providing organizations such as AA with data showing that quitting smoking is not 
associated with higher rates of alcohol use relapse and that continued smoking actually 
reduces the likelihood of achieving long-term sobriety,108 we can perhaps help to lessen 
its role as a perceived “crutch” for those with alcohol dependence. 
Limitations 
Because we are analyzing these data as observational, there is the potential for 
unmeasured confounding to bias our effect estimates. It is possible that those who were 
able to quit smoking may differ from non-quitters in ways that are difficult to control for 
using standard covariate adjustment. In addition, we merged the “Hispanic” and 
“Asian/Pacific Islander” categories into a single category to account for the small sizes of 
these groups. This may have hampered our ability to adequately control for the 
confounding influence of race/ethnicity for these analyses. It is important that future 
work examining the influence of smoking cessation on MH symptoms and binge drinking 
incorporates larger numbers of racial and ethnic minorities. It is also challenging to 
establish the direction of effects between smoking cessation and MH symptoms and 
binge drinking behavior. We attempted to address this issue by controlling for baseline 
levels of the outcome variables. Another limitation is that the OPTIN trial was not 
sufficiently powered to examine whether the proactive outreach intervention itself had an 
effect on binge drinking, depression, or anxiety. This is an important area of research to 
pursue if we are to demonstrate that efforts to promote smoking cessation, including 
population-level interventions like OPTIN, are effective for improving the MH of 
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smokers with SMI. In addition, while rates of smoking cessation were comparatively high 
in our study relative to similar trials, only 14.1% (n=248) of the sample achieved 
cessation. The small size of the smoking quitter group limited the power of our analyses 
and increased the likelihood of Type 2 errors. This was particularly problematic in our 
analysis of the binge drinking outcome, which had small numbers of participants in the 
“1 day”, 2-3 days”, and the “more than 3 days” categories. To address this limitation, 
post-hoc analyses were performed on the combined SMI and non-SMI sample in order to 
examine the main effect of prolonged smoking cessation on binge drinking. The timeline 
of our measures also precluded us from assessing any effects that smoking cessation may 
have on MH symptoms and alcohol use immediately following a quit attempt. This is 
valuable information to have in order to build a more complete picture of how cessation 
impacts these outcomes in both the short term and the long term. In addition, we do not 
have measures of functional impairment to help validate the SMI categorizations which 
would help ensure that the smokers in the SMI category were experiencing a high degree 
of life impairment. There is also a potential for selection bias as it is plausible that losses 
to follow-up were associated with the exposure (smoking cessation) and the outcomes 
(MH symptoms, binge drinking).   
Conclusion 
It is important that we actively work to counter the narrative that smoking cessation is not 
a treatment priority for smokers with SMI. Given the reductions in problematic MH 
symptoms and binge drinking experienced by smokers who quit, our findings bolster the 
case for providing all smokers with advice to quit and access to cessation resources, 
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particularly those with co-morbid MH and alcohol use disorders. As smoking is 
responsible for much of the excess mortality experienced by those with SMI,13 it is vital 
to shape an alternative narrative which stresses that smoking cessation is in fact one of 
the most pressing treatment priorities for this population. Going forward we must work to 
disseminate this information to healthcare providers, organizations like AA, and to 
smokers themselves in order to eliminate this health disparity.  
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Conclusion 
Overview 
It is clear that socioeconomically disadvantaged smokers with SMI are a uniquely 
vulnerable population with respect to smoking-related morbidity and mortality. As such, 
it is imperative that we work to better understand the barriers and facilitators to treatment 
utilization and cessation among these smokers. This dissertation involves secondary data 
analyses of OPTIN trial data. OPTIN trial participants were a sample of 
socioeconomically disadvantaged smokers enrolled in Minnesota Health Care Programs; 
a publicly-subsidized state health insurance program comprised of Medicaid and 
MinnesotaCare. Using DHS data drawn from a 2-year period prior to study initiation, 
ICD-9 codes indicating diagnoses of schizophrenic disorders, psychotic disorder, bipolar 
disorders, and major depressive disorder were used to categorize participants in SMI 
(n=1044) or non-SMI (n=1277) groups. 
Summary of Research 
The three research studies that comprise this dissertation sought to elucidate the factors 
that influence the cessation process among socioeconomically disadvantaged smokers 
with SMI.  
Research Study 1 
As it is increasingly acknowledged that healthcare providers play a key role in the 
cessation process, the first study explored whether SMI affects the nature of smokers’ 
interactions with their healthcare providers, and whether these interactions affect the 
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propensity with which they utilize cessation treatments. The bulk of the existing literature 
suggested that patients with SMI were likely to experience heightened levels of physician 
bias and lower rates of care for co-morbid conditions like tobacco use. As such, it was 
hypothesized that there would be a strong negative association between SMI and 
cessation treatment utilization at 12-month follow-up.  
Contrary to expectations, smokers with SMI actually had significantly higher rates of 
cessation treatment utilization at follow-up including medication use (41.9% vs. 29.8%, 
p<0.001), counseling use (14.3% vs. 11.1%, p=0.045), and use of any form of cessation 
treatment (44.7% vs. 31.6%, p<0.001). It was further noted that smokers with SMI 
reported higher baseline rates of physician-delivered advice to use medications and 
advice to use treatments other than medications than smokers without SMI. These 
physician advice variables were in turn associated with higher rates of cessation treatment 
utilization at follow-up. Analyses of the indirect effects of SMI on cessation treatment 
utilization through physician-delivered cessation advice indicated partial mediation by 
these variables. The proportion of the total effect of SMI on treatment utilization that was 
mediated by these physician advice variables ranged from 4.1% to 13.4%, depending on 
the mediator and outcome in question. With respect to the third proposed mediator, 
analyses revealed no evidence of associations between SMI and levels of perceived 
physician bias, or between perceived physician bias and cessation treatment utilization. 
Given the well-documented associations between SMI and lower rates of cessation-
related care and heightened levels of physician bias noted in previous studies, we 
conducted post-hoc sensitivity analyses to help elucidate these seemingly counterintuitive 
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findings. Using a measure of clinical encounter frequency derived from DHS data, 
analyses revealed comparatively high rates of physician contact in the SMI group relative 
to the non-SMI group. It was also found that adding clinical encounter frequency as a 
covariate to our regression models resulted in a large attenuation of the effect of SMI on 
treatment utilization.  
These findings suggest that SMI smokers’ comparatively high rates of cessation 
treatment utilization are at least partially explained by the heightened frequency with 
which they interact with their healthcare providers, likely due to the fact that these 
smokers were enrolled in MHCP and had access to free or reduced cost healthcare. The 
heightened rate of physician contact may help to explain the disparity in cessation care 
observed between the SMI participants in the present study and those in past studies, 
where these individuals may have had more variable access to healthcare. Furthermore, 
the finding that smokers in the SMI group had higher rates of clinical encounters and 
were more likely to report having a “regular” doctor may have resulted in these patients 
feeling more comfortable with their healthcare providers and being less likely to perceive 
bias. 
It is difficult to generalize these findings to the broader population of low-income 
smokers due to variations in access to healthcare. However, the relatively high rates of 
physician-delivered cessation advice reported by smokers with and without SMI seem to 
suggest that expanding publicly-subsidized insurance programs like Medicaid may 
bolster rates of treatment utilization among low-income smokers. This may be 
particularly important for smokers with SMI as they often require a greater number of 
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quit attempts and need to utilize more treatment strategies before achieving cessation. 
This suggests that finding ways to maximize contact with their healthcare providers is a 
crucial step toward reducing smoking rates in this population. 
Research Study 2 
The second study examined whether proactive outreach strategies are an effective 
approach for minimizing healthcare provider and psychosocial barriers to treatment 
utilization and prolonged smoking abstinence among smokers with and without SMI. The 
proactive outreach intervention was meant to minimize individual-level barriers to 
cessation like low self-efficacy for quitting, address social environmental barriers 
including permissive social norms and low social support for quitting, and circumvent 
healthcare provider barriers by facilitating direct access to evidence-based cessation 
resources. Subsequent exploratory analyses investigated whether the intervention was 
significantly more effective for smokers with SMI compared to those without SMI for 
both the treatment utilization and the prolonged abstinence outcomes.  
As hypothesized, it was found that the intervention significantly increased rates of any 
form of treatment utilization in both the SMI group (51.6% vs 38.1%, p<0.001) and the 
non-SMI group (38.6% vs 25.8%, p<0.001). The intervention also increased rates of 
prolonged abstinence in the SMI group (14.7% vs 10.8%, p=0.070) and the non-SMI 
group (18.1% vs 12.8%, p=0.019). 
With respect to the exploratory aim, it was hypothesized that the intervention would be 
significantly more effective for smokers with SMI compared to those without SMI. 
Baseline analyses demonstrated that smokers with SMI in our sample lived in social 
	 106 
environments that were more conducive to smoking and had lower self-efficacy for 
quitting than those without SMI; barriers that the OPTIN intervention was designed to 
minimize through proactive outreach and motivational interviewing. However, there were 
no interactions between the intervention and SMI status on any of the outcomes tested. 
When examined in parallel, the effects observed in the SMI and non-SMI groups were 
similar in magnitude for the both the cessation treatment utilization and the prolonged 
abstinence outcomes.  
The similarity of effects for the treatment utilization outcomes observed in the SMI and 
non-SMI groups can be put in context by more thoroughly examining the healthcare 
characteristics of our sample. Through their enrollment in MHCP, all participants in the 
OPTIN study had access to free or reduced cost healthcare. This facilitated access to care 
seems to have been of particular benefit for the SMI smokers in our sample, as baseline 
analyses indicated that these smokers were more likely to report having a regular 
physician, had much more frequent interactions with their healthcare providers, were 
more likely to receive physician-delivered cessation advice, and had much higher rates of 
cessation treatment utilization than non-SMI smokers. The increased access to healthcare 
experienced by SMI smokers in our sample compared to those in the general population 
may have dampened the effectiveness of the intervention relative to that which was 
initially hypothesized. 
Despite the relatively supportive cessation environment that MHCP seems to be 
providing for smokers with SMI, our study suggests that proactive outreach is still 
effective for boosting rates of treatment utilization and provides preliminary evidence for 
	 107 
its effectiveness in boosting prolonged abstinence rates as well. These interventions may 
be especially useful for bolstering rates of counseling use among these smokers, which 
were lower than 5% at baseline among the smokers in our sample. When used in 
conjunction with cessation care provided through healthcare programs like MHCP, 
proactive outreach strategies may play an important role in reducing smoking rates 
among socioeconomically disadvantaged smokers with SMI. 
Research Study 3 
The third study examined the enduring conception that smoking cessation is deleterious 
for smokers with SMI, specifically with respect to MH symptom exacerbation and 
problematic alcohol use behaviors. Evidence suggests that these perceptions exist at both 
the individual level and at the level of the healthcare provider, and may contribute to a 
reluctance to recommend and/or engage in smoking cessation. Regressions modeled the 
effect of prolonged cessation on PHQ-9 depression scores, PROMIS anxiety scores, and 
past month binge drinking behaviors at 12-month follow-up among smokers with and 
without SMI while controlling for baseline levels of these variables. Given the lack of 
past research in these areas conducted among samples of smokers with SMI, these 
analyses were largely exploratory.  
Analyses revealed that smokers who achieved prolonged smoking cessation had far lower 
odds of binge drinking for 3 days per month than those who did not achieve cessation in 
both the SMI (OR=0.26, 95% CI: 0.09-0.76) and the non-SMI groups (OR=0.42, 95% CI: 
0.21-0.87). With respect to the MH outcomes, smokers who achieved cessation had lower 
PHQ-2 scores in both the SMI (2.37 vs 2.71, p = 0.042) and the non-SMI group (1.59 vs 
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1.75, p = 0.065). Smokers who achieved cessation also reported lower PROMIS anxiety 
scores in the SMI group (55.61 vs. 59.03, p <0.001), but this effect was not significant in 
the non-SMI group. 
Given the high rates of alcohol dependence disorder observed among smokers with SMI 
(34% in our sample), it is critically important to examine how problematic drinking 
behaviors are affected in the wake of smoking cessation. Despite this high rate of alcohol 
dependence, prolonged smoking abstinence was not associated with heightened rates of 
binge drinking. Indeed, a trend appeared such that smokers who quit had lower odds of 
past month binge drinking than those who remained smokers, although further research is 
needed to replicate this association. Our study also demonstrated that prolonged cessation 
was associated with lower levels of depression and anxiety among those with SMI. Taken 
together, these results counter the narrative that smoking cessation is not a treatment 
priority for smokers with SMI. Providing these smokers with more accurate information 
about the long-term effects of smoking cessation on MH symptoms and problematic 
substance use behaviors may help boost motivation to quit, and heighten these smoker’s 
perceiving ability to engage in quit attempts and successfully achieve cessation.  
Final Thoughts 
The aim of this dissertation was to identify how our healthcare apparatus can better serve 
socioeconomically disadvantaged smokers with SMI. The results of these studies suggest 
that, in general, the SMI smokers enrolled in MHCP are being provided with a 
comparatively supportive healthcare environment relative to what has been observed in 
past studies of smokers with mental illness. This resulted in unexpectedly high rates of 
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physician interaction, higher rates of cessation-related care, and ultimately higher rates of 
cessation treatment utilization. However, there is room for improvement. The promising 
results of the proactive outreach intervention with respect rates of cessation treatment 
utilization and prolonged abstinence suggest that these smokers still face barriers to 
cessation care. Given the time limitations imposed on many physicians, it may be useful 
to more widely implement systems that provide these smokers with referrals for external 
cessation resources and to increase coordination across healthcare providers. It is also 
plausible that more widespread implementation of proactive outreach strategies can help 
to supplement the care environment provided by MHCP. Our results helped counter the 
notion that smoking cessation is problematic for those with SMI by establishing that 
quitting is not associated with increases in deleterious MH symptoms or harmful drinking 
behaviors. It is vital that we actively distribute this information to healthcare providers 
and to smokers themselves to provide a more accurate depiction of how smoking 
cessation affects well-being. Given the centrality of social support organizations like AA 
in the lives of many smokers coping with alcoholism, it is also important to disseminate 
this information to resources that fall outside the scope of the traditional healthcare 
environment. We must treat the persistent high rates of smoking among 
socioeconomically disadvantaged smokers with mental illness as a public health priority, 
and continue working to reduce the smoking-related health and economic burdens borne 
by this population.  
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Appendix: Scale Measures 
Perceptions of Healthcare Provider Bias 
 
When considering your overall experience with your doctor or primary healthcare 
provider(s), whether or not they spoke to you about quitting smoking… 
 
          Strongly       Somewhat       Neither       Somewhat       Strongly 
            Agree           Agree           Agree/         Disagree         Disagree 
         Diasgree 
 
          a) I felt I was treated with respect and dignity. 
                      b) I felt my background and values were understood. 
                      c) I felt I was looked down on for the way I live my life. 
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Binge Drinking Behavior 
 
During the past 30 days, on how many days did you have 5 or more drinks of alcohol (4 
or more drinks if you are a woman)? 
 
1) 28 – 30 days (about every day)* 
2) 20 – 27 days (5 – 6 days a week, average)* 
3) 11 – 19 days (3 – 4 days a week, average)* 
4) 4 – 10 days (1 – 2 days a week, average)* 
5) 2 – 3 days in the past 30 days 
6) Once in the past 30 days 
7) I drank during the past 30 days, but I never drank 5 or more drinks on the same 
occasion† 
8) Didn’t drink any alcohol in the past 30 days† 
 
* Items merged into single category 
† Items merged into single category 
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Patient Health Questionnaire (PHQ-2) 
 
1) During the past 2 weeks, how often have you been bothered by having little interest or 
little pleasure in doing things? Would you say… 
 
1) Not at all 
2) Several days 
3) More than half the days 
4) Nearly every day 
 
2) During the past 2 weeks, how often have you been bothered by feeling down, 
depressed, or hopeless? Would you say… 
 
1) Not at all 
2) Several days 
3) More than half the days 
4) Nearly every day 
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PROMIS Anxiety 
 
In the past 7 days…   
          Never       Rarely       Sometimes       Usually       Almost       Always 
 
          a) I felt fearful. 
                      b) I felt anxious. 
                      c) I felt worried. 
                      d) I found it hard to focus on anything other than my anxiety. 
                      e) I felt nervous. 
                      f) I felt uneasy. 
                      g) I felt tense. 
 
 
 
 
 
 
 
 
 
 
 
